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SUMMARY 
Efficient innate defense mechanisms are the key to fight an invading pathogen early. 
Intracellular pathogens such as Legionella pneumophila have developed sophisticated 
mechanisms to manipulate these host cell processes and establish an intracellular niche 
for survival and replication. To overcome these microbial threats, host cells and host 
organisms as a whole have evolved a large repertoire of defense mechanisms. The 
balance between bacterial virulence strategies and defense pathways of the host finally 
determines the outcome of such bacterial encounters, resulting in microbial clearance 
or, in case of L. pneumophila, establishment of Legionnaires’ disease. Much progress 
has been made in order to understand the initial pathogen recognition. However, the 
effector mechanisms that finally lead to killing of L. pneumophila, and other 
intracellular bacteria are poorly characterized.  
The study presented here systemically examines the innate immune response against 
L. pneumophila on whole organism level as well as on a molecular level within 
macrophages, L. pneumophilas’ host cell. In vivo transcriptome analyses identify 
type I and II interferons (IFNs) as master regulators of the early pulmonary gene 
expression during L. pneumophila infection. Infection experiments in wild-type mice 
and mice lacking type I and/or II IFN signaling reveal a severe defect of antibacterial 
defense when IFN signaling is absent. CD11c+ cells were found to be the main targets 
of IFNs to restrict infection in the lung, and IFNs inhibited bacterial growth in CD11c+ 
alveolar macrophages ex vivo. Subcellular quantitative mass spectrometry shows that 
both IFNs substantially modify the protein composition of Legionella-containing 
vacuoles. Comparative network analysis, combining these proteome data with 
transcriptome data as well as public database data reveals distinct subsets of 
transcriptionally regulated IFN-stimulated genes (ISGs) on the one hand, but 
interestingly also exclusively spatially IFN-regulated vacuolar proteins. Among IFN-
regulated vacuolar proteins, Immunoresponsive gene 1 (IRG1) was identified as a 
central effector that restricts growth of L. pneumophila through production of the 
antibacterial metabolite itaconic acid in macrophages.  
Collectively, this study provides a comprehensive resource of IFN-mediated effects on 
gene expression and the bacterial vacuolar proteome, and uncovers a cell-autonomous 
defense pathway against L. pneumophila, which is mediated by IFNs, IRG1 and 
itaconic acid. 
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ZUSAMMENFASSUNG 
Effiziente Mechanismen der angeborenen Immunabwehr sind der Schlüssel zur 
schnellen Bekämpfung von eindringenden Pathogenen. Intrazelluläre Pathogene, wie 
z. B. Legionella pneumophila haben ausgefeilte Mechanismen entwickelt, um 
Wirtszellprozesse zu manipulieren und hierdurch eine intrazelluläre Nische zum 
Überleben und für ihre Replikation zu schaffen. Im Gegenzug haben Wirtszellen und 
Wirtsorganismen ein großes Repertoire an Abwehrmechanismen entwickelt, um sich 
vor intrazellulären Infektionen zu schützen. Die Balance zwischen bakterieller 
Virulenzstrategie und der Immunabwehr des Wirts entscheidet letztlich über den 
Ausgang einer solchen Infektion, was entweder zur erfolgreichen Beseitigung der 
Pathogene oder, im Falle von L. pneumophila, zur Manifestation der Infektion als 
Legionärskrankheit führt. Für das Verständnis der initialen Mechanismen der 
Pathogenerkennung wurden bereits große Fortschritte gemacht. Im Gegensatz dazu 
sind die Effektormechanismen, die letztlich zur Abtötung von L. pneumophila sowie 
anderer intrazellulärer Bakterien führen, unzureichend verstanden. 
Die hier vorgestellte Studie untersucht systematisch die angeborene Immunabwehr 
gegen L. pneumophila auf Ebene des gesamten Wirtsorganismus, sowie auf 
molekularer Ebene in Alveolar- und Knochenmarksmakrophagen. Mittels in vivo 
Transkriptomanalysen werden Typ I und II Interferone (IFN) als Hauptregulatoren der 
frühen pulmonalen Genexpression in der L. pneumophila-Infektion identifiziert. 
Infektionsexperimente in Wildtyp- und IFN-Rezeptor-defizienten Tieren offenbaren, 
dass Typ I und II IFNe maßgeblich die antibakterielle Abwehr gegen L. pneumophila 
vermitteln. Für die Bekämpfung der Infektion in der Lunge werden CD11c+ Zellen als 
wichtigste Empfänger der IFN-Signale identifiziert. Des Weiteren wird durch 
Behandlung von CD11c+ Alveolarmakrophagen mit IFNen ex vivo das intrazelluläre 
bakterielle Wachstum inhibiert. Mittels subzellulärer quantitativer 
Massenspektrometrie wird gezeigt, dass die Proteinkomposition der Legionellen-
enthaltenden Vakuole substanziell durch beide IFNe modifiziert wird. In einer 
vergleichenden Netzwerkanalyse werden diese Proteomdaten mit eigenen und 
öffentlich zugänglichen Transkriptomdaten verglichen. Hierdurch können klar 
abgegrenzte Untergruppen von einerseits transkriptionell durch IFN-regulierten 
Proteinen sowie andererseits ausschließlich räumlich IFN-regulierten Proteinen 
unterschieden werden. Unter den durch IFN an der Vakuole angereicherten Proteinen 
wird Immunoresponsive gene 1 (IRG1) als zentraler Effektor identifiziert, welcher das 
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Wachstum von L. pneumophila durch die Produktion des antibakteriellen Metaboliten 
Itaconsäure inhibiert. 
Zusammenfassend stellt diese Studie eine umfassende Ressource von IFN-vermittelten 
Effekten auf die Genexpression sowie auf das Proteom der bakteriellen Vakuole dar 
und deckt einen zellautonomen Abwehrmechanismus gegen L. pneumophila auf, 
welcher durch die IRG1-abhängige Produktion von Itaconsäure vermittelt wird.  
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1.1 Legionella pneumophila – an accidental pathogen 
1.1.1 History, epidemiology and biology 
In late July 1976 several veterans became sick with flu-like symptoms, including 
fever, chest pains, lung congestion, and tiredness, after they had attended the 
annually American Legion convention at the Bellevue-Stratford Hotel in 
Philadelphia, Pennsylvania. Within the next weeks a total of 182 cases were 
reported of which 147 had to be hospitalized and 29 died 1. No laboratory test could 
determine the cause of the mysterious illness, which quickly became known as the 
Legionnaires’ disease. It took more than half a year of intensive investigations until 
the causative agent was described as a Gram-negative bacillus finally termed 
Legionella pneumophila, reflecting its victims as well as the primarily caused 
disease, a severe pneumonia 2,3. Since then lots of outbreaks had been reported with 
high fatality rates of up to 32%. Many of these outbreaks were associated with 
contaminated cooling towers, hot and cold water systems, and whirlpool spas 4. 
Besides these point source outbreaks L. pneumophila becomes more and more 
recognized as one of the most common pathogens to cause community-acquired 
pneumonia 5–7. Risk factors associated with Legionella-infection include older age, 
solid organ transplantation, smoking, a history of cancer or hematologic 
malignancies, steroid therapy, other immunosuppressive treatments, and diabetes 
mellitus 8. The numbers of patients with those risk factors as well as the number of 
reported cases of legionellosis are increasing 9–11.  
In the environment L. pneumophila has been detected in virtually all sources of 
freshwater, including lakes, ponds, and rivers. Here the facultative intracellular 
bacterium persists and replicates as a parasite of freshwater protozoans 12,13. In man-
made water systems L. pneumophila almost exclusively exists within biofilms 14, 
were its ability to replicate seems to also depend on the presence of a protozoan 
host, while they are dispensable for L. pneumophila persistence 15. Human infection 
develops following inhalation of L. pneumophila-contaminated aerosols into the 
lung, phagocytic uptake of the bacteria and subsequent intracellular growth in 
permissive alveolar macrophages (Figure 1.1). Since person-to-person-
transmission has never been reported, human infection is a dead end for 
L. pneumophila, a therefore accidental pathogen 3,16. 
1.1 Legionella pneumophila – an accidental pathogen 
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Figure 1.1 Intracellular life cycle of L. pneumophila. See text for detailed description. 
1.1.2 The Legionella-containing vacuole 
Most phagocytosed microorganisms are trapped within phagosomes that mature 
into digestive vacuoles along the endocytic pathway, a process characterized by 
phagolysosomal fusion, acidification and finally degradation of the vacuolar 
content 17. Hallmarks of this process are the acquisition of the early and late 
endosomal markers Rab5 and Rab7, respectively, and finally the accumulation of 
further late endosomal proteins like lysosome-associated membrane glycoprotein 
(LAMP)-1 and cathepsin D 18–20. L. pneumophila-containing phagosomes in 
contrast bypass this phagolysosomal pathway by utilizing a type IV secretion 
system (T4SS) encoded by dot/icm genes to secrete ca. 300 effector molecules into 
the host cell 21. By manipulating the endolysosomal pathway and recruitment of 
ER-derived vesicles L. pneumophila creates a unique replication vacuole known as 
the Legionella-containing vacuole (LCV; Figure 1.1) 12,13,22,23. Early recruitment of 
the small GTPase Rab1 and the SNARE protein Sec22b, both known to be involved 
in fusion events of ER-derived vesicles, as well as the appearance of resident ER 
proteins like calnexin are key features of the LCV establishment 24,25. Electron 
microscopic studies revealed the association and fusion of ER-derived vesicles with 
the LCV within minutes upon phagocytosis. The LCV membrane becomes thinner 
1 Introduction 
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to resemble that of the closely attached ER vesicles. More and more ribosomes 
decorate the LCV membrane which appears to be completely comprised of rough 
ER within 4 to 6 h 22,26. Remarkably, a large proportion of vacuoles were found to 
be close and tightly associated with mitochondria. Their function at the LCV 
remains, however, unknown 22,26. The bacteria persist within this modified 
phagosome for 4 to 10 h without lysosomal fusion and acidification, before they 
start to replicate 26–29. Until 24 h post phagocytosis L. pneumophila can increase in 
number up to 100-fold within a single large LCV (Figure 1.1 ,Figure 1.2a, b) before 
lysis of the host cell is initiated (Figure 1.2c) to start a new round of 
infection 3,22,26,30. 
 
Figure 1.2 Fluorescent images of Legionella-containing vacuoles 24 h post infection. Bone 
marrow-derived macrophages (BMMs) were infected with DsRed-expressing L. pneumophila (red) 
for 24 h, fixed and nuclei stained with DAPI (blue). Cell borders were visualized by DIC microscopy 
(grey background). (a) A cell with a single large vacuole containing a large amount of bacteria is 
depicted. (b) Three individual vacuoles have formed within one single cell. (c) A large vacuole has 
disrupted and bacteria are released from the infected cell. Scale bar indicates 10 µm. 
 
While intracellular pathogens such as L. pneumophila manipulate host cell 
processes in order to establish an intracellular niche for survival and replication, 
host cells and host organisms as a whole have evolved defense mechanisms to 
restrict infection. Among them, intracellular defense pathways appear to be of 
particular importance for fighting L. pneumophila pneumonia (see chapter 1.3 
“Immune defense against L. pneumophila infection”, p. 19). The balance between 
bacterial virulence strategies and defense pathways of the host finally determines 
the outcome of such bacterial encounters, resulting in microbial clearance or 
establishment of Legionnaires’ disease. 
a b c
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1.2 The immune system 
Multicellular organisms are continuously in close contact with microorganisms like 
viruses and bacteria. Many of these close associations are of benefit for both sides, 
like the microbiota within the human gut, providing habitat and nutrient supply to 
the microorganisms on the one side, and support of digestion as well as vitamin 
supply for the host on the other side 31. In contrast, several other microorganisms 
shift this balanced co-existence in order to exploit and thereby impair the host and 
are therefore defined as pathogens. To counteract this process and defend 
themselves, multicellular organisms have evolved strategies and mechanisms to 
discriminate between self and non-self and to distinguish - to some extend - 
beneficial symbionts from pathogenic threats. In vertebrates there are two types of 
interconnected defense systems, the innate and the adaptive immunity. Key 
distinguishing feature between both are the employed types of receptors to detect 
the pathogen. While the innate defense relies on germ line-encoded pattern 
recognition receptors (PRRs) with broad specificity for highly conserved microbial 
patterns 32, the adaptive defense makes use of extremely diverse, randomly 
generated but highly specific antigen receptors 33. Historically both types of the 
immune system have been viewed as an evolutionary old and primitive innate 
immune system and a highly developed and specified adaptive immune system. 
However, this might have been oversimplified since an increasing amount of data 
demonstrates a high degree of interdependence between both parts as well as a high 
level of regulatory networks to control and direct each other 34–38.  
1.2.1 The innate immune system 
After overcoming the host protecting mucosal barriers, invading pathogens are 
typically confronted with the innate immune system. Serving as the first line of 
defense the innate immune response is characterized by a fast initiation and 
comprises a collection of features, including tightly controlled antimicrobial 
effector-molecules that directly target and kill pathogenic microorganisms. A 
fundamental aspect of the innate immune system is the ability to detect molecular 
structures unique to microorganisms, and thereby enabling a self vs. non-self-
discrimination. This recognition relies on the ability of PRRs to detect so-called 
pathogen-associated molecular patterns (PAMPs), although the term pathogen-
1 Introduction 
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associated is in some way misleading since many PAMPs are not unique to 
pathogens but also common to non-pathogenic microorganisms. PAMPs are 
defined by three main criteria: (i) they are invariant among microorganisms of a 
given class, ensuring the recognition of a wide range of microbes, (ii) they are 
products of pathways unique to microorganisms (with few exceptions, see below) 
rendering them optimal for self vs. non-self-discrimination, and (iii) they have 
essential roles within the microbial physiology and are indispensable for their 
survival, limiting the ability to modify or change their characteristics in order to 
evade the innate immune recognition 32. Typical bacterial PAMPs include cell wall 
components like lipopolysaccharide (LPS), and peptidoglycan. Nucleic acids are 
another group of PAMPs important for viral and bacterial detection. However, since 
nucleic acids per se are not unique to microorganisms the indispensable self vs. 
non-self-discrimination here is based on chemical modifications within microbial 
nucleic acids 39–41 or the cellular non-physiological localization of nucleic acids, 
e.g. within the cytosol. However, since this system is not free of mistakes, 
autoimmune diseases can develop when it is miss-regulated 42. Rapidly upon host 
cell-pathogen contact, the PRR-PAMP interaction induces a wide variety of 
protective antimicrobial responses, including cell-autonomous, host cell-intrinsic 
mechanisms, as well as recruitment and activation of innate effector cells like 
neutrophils and NK cells 43–45.  
Central players within the innate immune system are professional phagocytes, 
including macrophages, neutrophils and dendritic cells (DCs). Phagocytosis 
describes the process of uptake of large solid particles, including microorganisms 
into intracellular membrane-bound vacuoles known as phagosomes 46 and is the 
crucial direct and indirect first step for many innate and adaptive, respectively, 
immune functions. Resident macrophages serve as sentinel cells, e.g. in brain 
(microglia), skin (Langerhans cells), liver (Kupffer cells) and lung (alveolar 
macrophages) and are often the first immune cells that get into contact with 
invading microbes. Their primary role is to find and remove pathogens via 
phagocytosis followed by intracellular degradation, as well as secretion of 
cytokines, signaling molecules that guide the way for other immune cells to the site 
of infection 47–49. Among these recruited immune cells, neutrophils are the first to 
arrive in large numbers. They are professional killers especially of extracellular 
1.2 The immune system 
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bacteria and fungi 50 and further amplify and modify the immune response by 
additional secretion of cytokines 51–54. Besides neutrophils, monocytes are also 
recruited to the site of infection and are essential mediators of protective immune 
defense against a wide range of microbes 55. Upon arrival they can differentiate into 
various macrophage or DC subsets depending on the cytokine milieu and the 
surrounding tissue, thereby replenishing the tissue resident cell populations and/or 
directly contributing to microbial clearance 55. DCs finally link the innate and 
adaptive immune system and guard against infections in virtually all tissues 34. By 
presenting pathogen-derived antigens in the context of major histocompatibility 
complex (MHC) molecules, they activate and regulate the subsequent adaptive 
immune response, thereby fulfilling a second highly important function of the 
innate immune system 35,44. 
1.2.1.1 Innate detection mechanisms – inevitable first step for efficient 
immune responses  
The key for initiation of an appropriate and efficient immune response is an early 
and sensitive detection of the invading microbial threat. This is achieved by a 
limited number of germ line-encoded receptors, the PRRs, which detect a broad 
spectrum of unique microbial signature molecules, known as PAMPs 43,44. 
Toll-like receptors 
The first identified and therefore best understood group of PRRs are the Toll-like 
receptors (TLRs) 56. Belonging to the group of membrane-bound PRRs they are 
localized within the plasma- or endosomal membrane, thereby surveilling the cell 
surface as well as the phagocytosed content of endo- and phagosomes. Their 
respective ligands cover a broad spectrum of PAMPs ranging from LPS (TLR4) 
and flagellin (TLR5) to RNA (TLR3, TLR7, TLR8) and DNA (TLR9), enabling 
them to recognize viruses, bacteria, fungi and parasites. Upon PAMP recognition 
TLRs initiate a downstream signaling cascade via the adapter molecules MyD88 or 
TRIF and induce via the transcription factors NF-B or IRF3 the expression of 
proinflammatory cytokines and type I IFNs 57. 
Nod-like receptors 
The second group of PRRs comprises the nucleotide-binding, oligomerization 
domain (NOD)-like receptors (NLRs). NLRs are a large group of PRRs defined by 
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a common C-terminal leucine-rich repeat (LRR) domain, a central NOD domain 
and an N-terminal protein interaction domain. The latter is used to further subdivide 
the NLRs in the five subfamilies NLRA (with an acidic transactivation domain), 
NLRB (with a baculovirus inhibitor of apoptosis repeat (BIR) domain), NLRC 
(with a caspase activation and recruitment domain (CARD)), NLRP (with a pyrin 
domain (PYD)) and NLRX (with an unknown domain) 58. NLRs are cytosolic 
PRRs, with the mitochondrial membrane-localized NLRX1 being the only 
exception. Many NLRs are poorly characterized, however, the few well studied 
NLRs reveal already a broad spectrum of ligands and modes of action 45,58. 
Among the best-understood NLRs are NOD1 and NOD2, both belonging to the 
NLRC subfamily. While NOD1 detects meso-diaminopimelic acid found primarily 
in the cell wall of Gram-negative bacteria, NOD2 recognizes the muramyl dipeptide 
(MDP) MurNAc-L-Ala-D-isoGln, which is conserved in peptidoglycans of Gram-
positive and Gram-negative bacteria. Both subsequently signal via RIP2 and NF-kB 
to induce proinflammatory cytokines. Additionally, NOD1 and NOD2 were 
recently indicated to activate type I IFNs via the transcription factors IRF7 and 
IRF3, respectively, in some specific situations 58. 
A further well studied and important member of the NLRs is NLRP3. NLRP3 is 
probably the PRR with the widest spectrum of activators ranging from PAMPs like 
microbial RNA and certain forms of DNA, bacterial pore-forming toxins, and the 
peptidoglycan derivative MDP to molecules like ATP, gout-associated uric acid 
crystals, aluminum salts and silica crystals 45,59. In contrast to NOD1, NOD2 and 
the TLRs, NLPRP3 activation does not cause a transcriptional response but rather 
leads to the assembly and activation of a large hetero-multimeric protein complex 
called inflammasome. Besides a receptor molecule such as NLRP3, this complex 
often contains the adapter molecule apoptosis-associated speck-like protein 
containing a carboxy-terminal CARD (ASC) and the caspase-1 60. Activation of 
canonical inflammasomes culminates in the caspase-1-dependent proteolytic 
processing of NF-B-dependently produced proIL-1 and proIL-18 into the mature 
and secreted cytokines IL-1 and IL-18, respectively. Additionally caspase-1 
activation can also lead to pyroptosis, a highly inflammatory form of programmed 
cell death 59.  
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Another inflammasome depends on NLRC4, which also leads to casspase-1 
activation and IL-1 secretion as well as pyroptosis. The role of ASC in this setting, 
however, remains elusive, since NLRC4 possesses an own CARD domain, making 
it possible to directly interact with caspase-1, independently of ASC 58. Consistent 
with this, there had been described two modes of action for NLRC4 
inflammasomes. While IL-1 processing and secretion is strongly ASC-dependent, 
pyroptosis is not 58. Only recently it was demonstrated that members of the NLR 
family, apoptosis inhibitory protein (NAIP) gene family are necessary to confer 
ligand specificity to the NLRC4 inflammasome 61. 
RIG-I-like receptors 
The RIG-I-like receptors (RLRs) comprise only three members, retinoic acid-
inducible gene I (RIG-I), melanoma differentiation-associated gene-5 (MDA-5) and 
laboratory of genetics and physiology 2 (LGP2), which are all cytosolic RNA 
sensors 62,63. However, while RIG-I and MDA5 primarily activate the adaptor 
molecule mitochondrial antiviral signaling (MAVS) and subsequently the 
transcription factors IRF3/7 to stimulate type I IFN expression, LGP2 appears to 
act as a modulator of RIG-I and MDA5. RLRs play a pivotal role in detection of 
RNA viruses and can also contribute to the detection of AT-rich cytosolic DNA, a 
mechanism which involves the RNA polymerase III dependent transcription of 
DNA into the RIG-I ligand 5’-triphosphate-dsRNA 62. 
Cytosolic DNA sensors 
Cytosolic DNA sensors can be classified as a fourth group of PRRs that is defined 
rather by its recognized ligand than by structural similarities. Basically all members 
of this relatively new group of PRRs have been identified within the last 5 – 6 years, 
with ZBP1/DAI being an exception. Common to several of the members is the 
ability to induce type I IFNs via the central adapter and sensor molecule stimulator 
of interferon genes (STING) and the transcription factor IRF3 64,65. 
Recently, cGAS a fascinating new player of the intracellular DNA sensing has been 
identified 66. Upon DNA binding cGAS (cGAMP synthase) synthesizes a cyclic 
dinucleotide called cGAMP (cyclic-GMP-AMP), which in turn serves as a direct 
ligand for STING to activate downstream signaling 67. Besides STING-dependent 
type I IFN induction, other signaling pathways are also activated upon cytosolic 
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DNA detection. absent in melanoma 2 (AIM2), for example, forms together with 
ASC and caspase-1 an inflammasome to regulate IL-1 and IL-18 production as 
well as pyroptosis 64,68,69. 
1.2.1.2 IFNs and their downstream signaling 
Type I IFNs 
Type I IFNs comprise a family of several subtypes of IFN, IFN as well as some 
further, less well characterized IFNs and can be produced by basically all cell types. 
All type I IFNs share the same receptor, the ubiquitously expressed IFN receptor 
(IFNAR), composed of the IFNAR1 and IFNAR2 subunits 70–73. The canonical 
IFNAR signaling relies on the JAK-STAT pathway. Receptor binding activates 
Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) by autophosphorylation and 
subsequently leads to tyrosine phosphorylation of signal transducer and activator of 
transcription (STAT) family members, including STAT1, 2, 3, 5 in virtually all 
cells, as well as STAT4 and 6 in lymphocytes 71,74. The classical IFNAR signaling 
pathway leads to formation of a heterotrimeric complex consisting of STAT1, 
STAT2 and IRF9 called IFNstimulated gene factor 3 (ISGF3). Upon formation, 
ISGF3 translocates into the nucleus to bind to specific IFN-stimulated response 
element (ISRE) sites within the promoter region of so-called interferon stimulated 
genes (ISGs) and induce their expression 74,75. IFNAR activation can also lead to 
the formation of STAT1 homodimers (also known as gamma-activated factor, 
GAF), which bind to IFN activated sites (GAS) within ISG promoter 
regions 71,74,76,77. Additionally, STAT3 or STAT4 homodimers can mediate 
alternative, not-ISG-inducing signaling events downstream of IFNAR 74. Notably, 
a recent report showed that a subset of ISGs can also be induced by an IFNAR2-
independent binding of IFN to IFNAR1 alone 78 (Figure 1.3). 
Type II IFN 
While type I IFNs comprise a family of different IFNs, IFN is the only type II IFN, 
which is, in contrast to type I IFNs, produced only by few specialized cell types, 
such as NK cells and T cells 79. It binds to the IFN receptor (IFNGR), a 
heterotetrameric complex consisting of two chains of IFNGR1 and two chains of 
IFNGR2 80,81. IFN-IFNGR binding activates JAK1 and JAK2, leading to 
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phosphorylation of STAT1, which subsequently forms a homodimeric complex 
known as GAF and translocates into the nucleus 79. Here GAF binds to GAS sites 
in the promoter region of ISGs and induces their expression 79,82. The potential of 
IFN to induce via IFNGR-mediated signaling the formation of ISGF3 and thereby 
genes possessing only an ISRE but no GAS site is, however, controversial 71,74,79 
(Figure 1.3). 
 
Figure 1.3 Overview of signaling cascades initiated by type I and/or II IFNs 74. Numbers of 
ISGs induced by type I and II IFNs are according to the ISG database INTERFEROME and were 
published elsewhere 83.  
In summary, a main consequence of IFN signaling, either by type I or type II IFNs, 
is the transcriptional induction of ISGs. However, while some ISGs are regulated 
by both, IFN and IFN, others are selectively regulated by either IFN or 
IFN 84.  
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1.2.1.3 Effector mechanisms induced by IFNs 
More than half a century ago Isaacs and Lindenmann described a “new factor […] 
recognized by its ability to induce interference” of the growth of influenza virus in 
fragments of chicken chorio-allantoic membrane upon pre-treatment with heat-
inactivated influenza virus 85. This factor subsequently was termed interferon, and 
is today known as type I IFN. Since then, much progress has been made in 
elucidating the underlying mechanisms of this interfering action. Today it is well 
established that this relies on the stimulation of the expression of interferon 
stimulated  genes  (ISGs),  a  mechanism  shared  by  type  I  and  type  II  IFNs 
(Figure 1.3). IFNs are among the most potent modulators of gene expression and 
recent advancements in large scale analyses like microarray technologies led to the 
identification of almost 1500 genes to be positively regulated by type I and/or 
type II IFNs 82,83. Interestingly, almost half of all the identified ISGs are regulated 
by both IFNs 83, possibly reflecting the shared and overlapping signaling pathways 
or alternatively, the presence of ISRE as well as GAS sites within the promoter 
region of many of those genes.  
Traditionally type I IFNs have been associated with antiviral immunity, while 
type II IFN is thought to defend against non-viral pathogens. However, this 
differentiation might have been oversimplified 86. Many recent large scale studies 
addressed the function of those ISGs and several were identified to act antiviral or 
being involved in pattern recognition processes 87–95. However, the exact molecular 
mechanisms of most of the known ISGs remains largely unknown 82. 
ISGs with antiviral function 
Many type I IFN-induced ISGs have been found to contribute to anti-viral defense, 
including proteins of the oligoadenylate synthase (OAS) 96, IFN-induced protein 
with tetratricopeptide repeats (IFIT) and IFN- inducible transmembrane (IFITM) 97 
families as well as virus inhibitory protein, endoplasmic reticulum-associated, IFN-
inducible (viperin) 98 and ISG15 99. These ISGs were shown to confer host defense 
at various stages of viral infection and the intracellular replication cycle. While 
members of the OAS and IFIT families are involved in the recognition of viral 
nucleic acids 96,97 thereby controlling and directing subsequent steps, IFITMs are 
thought to interfere with viral entry and uncoating 82,97. ISG15, an ubiquitin-like 
protein that can be transferred to pathogen and host proteins in an ubiquitinylation-
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like process called ISGylation, can modify cellular host proteins as well as viral 
proteins. While ISGylation of the host protein HERC5 is thought to stabilize IRF3 
and thereby augmenting the antiviral IFN signaling, direct ISGylation of viral 
proteins might interfere with viral assembly 82,99. Viperin finally can interfere with 
host cell metabolism and signaling events, although the exact mechanisms remain 
elusive, but is also thought to inhibit viral assembly 82,98. In the case of influenza 
virus this might be due to the disruption of ER-derived lipid rafts that transport viral 
envelope proteins to the plasma membrane 100.  
Currently little experimental evidence exists, that these ISGs with established 
antiviral functions might also target intracellular bacteria or parasites. However, the 
fact that they are highly expressed also upon bacterial infection or stimulation with 
bacterial PAMPs like LPS led to the speculation that some of them might exert also 
antibacterial functions 97,98,101. 
IFN inducible GTPases as antibacterial and antiparasitic acting ISGs  
Besides ISGs with established antiviral functions, several ISGs have been found to 
be crucial for antibacterial and antiparasitic defense. Among those, several belong 
to a large superfamily of proteins known as IFN inducible GTPases. These GTPases 
can be further subdivided into four subfamilies namely guanylate binding proteins 
(GBPs), immunity-related GTPases (IRGs), myxoma (MX) resistance proteins and 
very large inducible GTPases (GVINs) 102. All of which are inducible by 
type I IFNs, while GBPs, immunity-related GTPases and GVINs are also induced 
by type II IFN 102. Several immunity-related GTPases and GBPs have well 
established roles in cell-autonomous defense against intracellular bacteria and 
parasites, including Salmonella enterica serovar Typhimurium (S. Typhimurium), 
Listeria monocytogenes and Toxoplasma gondii. In contrast MX proteins are known 
to be involved in antiviral defense, including HCV and influenza viruse 102, whereas 
GVINs are poorly characterized. 
Immunity-related GTPases where the first IFN-inducible GTPases found to be 
important for defense against intracellular bacteria and parasites 103,104. They 
comprise a group of proteins with approximately 47 kDa in size and are therefore 
also known as p47-GTPases 104,105. Most members were found to localize to 
pathogen containing vacuoles ranging from bacterial phagosomes and chlamydial 
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inclusion bodies to protozoan parasitophorous vacuoles 102. Partially contrasting 
this view, a recent report showed that IRGM1 and IRGM3 reside on “self” 
organelles including lipid droplets within the host cell rather than on pathogen-
containing vacuoles that harbored Chlamydia trachomatis or T. gondii. While 
IRGM1/3 decorated lipid droplets were guarded from accumulation of other 
immunity-related GTPases and GBPs, IRGM1/3-stripped lipid droplets became 
highly affine for further immunity-related GTPase /GBP-association. IRGM1/3 are 
thus thought to help to discriminate “self” organelles from pathogen-containing 
“non-self” vacuoles that are then targeted by further immunity-related GTPases and 
GPBs to exert the effector function 106.  
The group of immunity-related GTPases can be further subdivided into GKS- and 
GMS-containing immunity-related GTPases, based on their canonical (lysine-
containing) and non-canonical (methionine-containing) G1 motifs within the 
conserved catalytic GTPase domain 107–109. The GMS subclass in mice includes 
IRGM1-3, which seem to act as intrinsic regulators, that control further effector 
molecules including other immunity-related GTPases 82. In contrast the GKS 
subclass proteins are thought to act as effector-immunity-related GTPases and may 
operate in a membranolytic way on pathogen-containing vacuoles, as shown for 
IRGA6 and IRGB10 82. Among the immunity-related GTPases, IRGM1 is thought 
to be a master regulator, a view that is supported by reports showing increased 
susceptibility of mice lacking IRGM1 to a broad range of pathogens, including 
Mycobacterium tuberculosis, M. avium, S. Typhimurium, L. monocytogenes, 
C. trachomatis, T. gondii and Trypanosoma cruzi 102. 
GBPs are highly conserved throughout the vertebrate lineage and belong to the most 
strongly IFN-induced proteins 102,109. All members of this subfamiliy are 
approximately 65 kDa in size and are therefore also known as p65-GTPases 108,109. 
Although initially thought to be important for antiviral defense 104, many of them 
were shown to target to pathogen-containing vacuoles (e.g. C. trachomatis, 
M. bovis, and T. gondii) as well as directly to cytosolic pathogens (e.g. 
L. monocytogenes, Shigella flexneri, S. Typhimurium and, Francisella tularensis 
subspecies novicida) that have escaped their vacuole 82,110,111. Recent reports have 
now demonstrated the importance of GBPs in antibacterial defense and shed some 
light on how GBPs mediate host resistance 112–116. A family-wide siRNA-screen 
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identified GBP1, GBP6, GBP7 and GBP10 to promote cell-autonomous resistance 
against M. bovis BCG and L. monocytogenes in IFN-activated macrophages. 
Further functional characterization showed that GBPs might coordinate a potent 
oxidative program by targeting members of the NOX protein family to the vacuole 
which contribute to pathogen killing by production of reactive oxygen species 
(ROS) (see chapter “Cytotoxic gases – highly efficient but unspecific”, p.16) 
Additionally, GBPs were shown to promote the delivery of antimicrobial peptides 
to autophagolysosomes, which killed mycobacteria when the Mycobacterium-
containing vacuole fuses with these autophagolysosomes 112. Another report 
demonstrated, that GBP5 is involved in assembly of the NLRP3 inflammasome, 
specifically in response to bacteria 114. Also the AIM2 inflammasome was found to 
be GBP-dependently activated. This seemed to involve direct targeting of cytosolic 
F. novicida leading to release of bacterial DNA which then can activate 
AIM2 110,111. Furthermore, it was shown that GBPs are involved in activation of the 
non-canonical caspase-11 inflammasome 115,116. This process most likely relies on 
GBP-mediated lysis of pathogen-containing vacuoles and thereby releasing the 
pathogens into the cytosol where LPS can then be directly detected by caspase-11 
leading to pyroptotic cell death 116,117.  
IRG1 – a long known ISG with newly described functions 
Immunoresponsive gene 1 (IRG1) was first identified 20 years ago as a gene 
strongly induced shortly upon LPS stimulation in RAW264.7 macrophages 118. 
However, except one report showing IRG1 to be highly induced by several 
proinflammatory stimuli like TNF, IL-1 as well as type I and II IFNs and 
reporting its mitochondrial localization 119, the role of IRG1 in immune defense and 
its mechanism of action remained largely elusive. First evidence for a protective 
function of IRG1 came from studies in neuronal cells, indicating a reduced 
susceptibility to positive-stranded RNA viruses when IRG1 was overexpressed 120. 
This was followed by another report identifying IRG1 as an enzyme that links 
cellular metabolism to immune defense. The enzyme was shown to decarboxylate 
the TCA cycle intermediate cis-aconitate into itaconic acid 121. Itaconic acid was 
known for a long time to interfere with microbial metabolism by inhibiting 
isocitrate lyase-activity 122, an enzyme important for the glyoxylate shunt which is 
used by bacteria, but not animals, when growing on acetate and fatty acids as carbon 
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source 123. Additionally it was shown, that M. tuberculosis persistence in 
macrophages and mice relies on isocitrate lyase-activity 124 and that Yersinia pestis, 
P. aeruginosa as well as other intracellular bacteria possess an operon encoding for 
three enzymes that are responsible for itaconic acid degradation and known to be 
important for pathogenicity 125. Taken together, IRG1 seems to inhibit intracellular 
bacteria via itaconic acid-mediated inhibition of bacterial metabolism. Finally two 
groups independently found a role of IRG1 in ROS production 126,127. The first study 
described a more systemically role of IRG1-dependent ROS production in LPS 
tolerance 126. The second study found that IRG1 is necessary for fatty acid 
-oxidation-driven mitochondrial ROS production and IRG1 depletion resulted in 
reduced mROS production and subsequently in defective bactericidal activity 
against S. Typhimurium 127. 
Cytotoxic gases – highly efficient but unspecific 
Cytotoxic gases, which include reactive oxygen and nitrogen species (ROS and 
RNS, respectively) are among the most ancient forms of cell-autonomous defense. 
They act by targeting a diverse range of pathogen- and host-derived 
macromolecules in a rather unspecific manner, including nucleic acids, lipids and 
proteins and therefore have to be tightly regulated 82.  
A well-studied example of IFN-driven RNS production is the NO-synthesis via the 
inducible NO-synthase (iNOS). iNOS has long been known to be regulated by 
IFN 128 as well as IFN/ 129. NO, which is produced from L-arginine and 
molecular oxygen is thought to exert antimicrobial activity by direct effects on 
DNA including induction of mutations and inhibition of repair and synthesis, 
inhibition of protein synthesis, modification of proteins by S-nitrosylation, ADP-
ribosylation or tyrosine nitration, inactivation of enzymes or by peroxidation of 
membrane lipids 130. A relevant role for iNOS in host defense was shown for 
intracellular parasites like Leishmania major and T. gondii as well as intracellular 
bacteria including M. tuberculosis, S. Typhimurium and L. monocytogenes, 
however iNOS seems to be dispensable for defense against L. pneumophila 
infection 131. In accordance with the well-established role in the defense against 
many intracellular pathogens, iNOS was shown to localize to phagosomes of 
internalized latex beads when macrophages were pretreated with IFN 132. 
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ROS, the second group of cytotoxic gases, are produced by different cytokine-
inducible oxidoreductases, namely NADPH oxidases (NOXs), which directly 
catalyze the production of O2
– and dual oxidases (DUOXs) which produce H2O2 
82, 
respectively. Recently, subunits of the NADPH oxidase have been shown to interact 
with the IFN-inducible GBP7 (see chapter “IFN inducible GTPases as antibacterial 
and antiparasitic acting ISGs”, p. 13), which might act as a bridging protein to target 
these subunits to phagosomal membranes for NADPH oxidase assembly 112. 
Additionally another ISG, IRG1, has been implicated to be involved in ROS 
production 126,127 and thereby contributing to antibacterial host defense 127 (see also 
chapter “IRG1 – a long known ISG with newly described functions”, p. 15). 
Cell death 
IFNs can directly and indirectly regulate and modulate different forms of cell death. 
A IFNAR-dependent cell death has been described for many intracellular bacteria 
like F. tularensis, S. Typhimurium, M. tuberculosis and L. monocytogenes, which 
seems to be rather detrimental to the host 133. Additionally it was shown that also 
viral infection-induced type I IFNs can increase apoptosis of granulocytes which 
leads to a defect in clearance of bacterial super-infections by Gram-positive or 
Gram-negative pathogens 134. Besides apoptosis, also RIP3 kinase-dependent 
programmed necrosis (necroptosis) was linked to IFNAR-signaling upon 
stimulation with LPS, polyI:C or infection with S. Typhimurium 135,136. 
Additionally treatment with recombinant IFN and IFN was shown to induce 
RIP1/RIP3-dependent necroptosis under certain conditions, e.g. when the adaptor 
protein Fas-associated death domain (FADD) was missing 137. 
Besides these rather direct mechanisms, IFNs can contribute to host cell death also 
indirectly. By partially regulating the expression of inflammasome components like 
NLRP3, AIM2 and CASP1137 IFNs might prime cells for subsequent 
inflammasome activation. Moreover, several reports demonstrate an IFN-
dependent induction of AIM2-mediated cell death 110,111,138,139. IFN-driven 
expression of guanylate binding proteins, which directly target intracellular 
F. novicida led to the release of bacterial DNA, the activator of AIM2 110,111. 
Additionally, non-canonical caspase-11 inflammasome-induced pyroptosis was 
recently linked to IFN signaling 140,141, a process that most likely involves the 
transcriptional regulation of caspase-11 140 as well as the well-known 
1 Introduction 
 
18 
IFN-stimulated GBPs (see also chapter “IFN inducible GTPases as antibacterial and 
antiparasitic acting ISGs”, p. 13) 115,116. 
Taken together, the large number of genes regulated by IFNs leads to a highly 
diverse array of defense mechanisms directed by IFNs and executed by their ISGs. 
While the loss of single ISGs only occasionally results in severe immune defects, 
most likely due to compensatory mechanisms via other ISGs, the lack of the entire 
IFN signaling often has dramatically consequences for the host. This severe 
phenotype as well as the high redundancy of IFN-driven effector mechanisms 
highlights the particular importance of IFNs and their ISGs for the cell-autonomous 
antimicrobial defense. 
1.2.2 The adaptive immune system 
Antigen presenting cells (APCs), namely DCs and macrophages, collect invading 
pathogens in the periphery to present their antigens in the context of MHC 
molecules. They migrate into lymph nodes and the spleen where T and B 
lymphocytes, the main players of the adaptive immune system, reside 142. Both cell 
types possess highly specific antigen receptors, according to the cell type known as 
B cell receptor (BCR) and T cell receptor (TCR), respectively 143. These receptors 
are randomly generated out of a virtually unlimited pool and therefore can 
potentially recognize virtually every antigen 33. The activated lymphocytes are then 
able to differentiate into several types of effector cells depending on the type of 
antigen (and thereby class of pathogen) they recognize 143. However, since the 
antigens detected by the BCR and TCR typically lack any information about the 
type of pathogen they are derived from, lymphocyte differentiation relies on further 
instruction signals derived from the APC 35,38. One well-known example are the 
MHC class I and II molecules. While antigens derived from the host cell cytosol, 
e.g. viral particles, are presented in the context of MHC-I and lead to the activation 
of CD8+ cytotoxic T cells, antigens from phagocytosed extracellular pathogens are 
presented in the context of MHC-II to activate CD4+ T helper cells. These CD4+ T 
cells then further differentiate into Th1, Th2 and Th17 cells depending on their 
transcription factor expression which is again controlled by cytokines from the 
APC 38,143. However, the instructional signaling is not a one way street leading from 
innate to adaptive cells, but goes also vice versa. Th1 cells for example are well 
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known producers of IFN, a cytokine with well-established functions in 
macrophage activation. Furthermore, Th17 cells are strong producers of IL-17, a 
cytokine that directs non-hematopoietic cells, including epithelial cells, to secrete 
chemokines that lead to neutrophil recruitment. Finally T cell derived cytokines 
also direct B cells to produce certain subclasses of antibodies, like Th1-derived 
IFN and Th2-derived IL-4 leading to the production of IgG2 and IgE, 
respectively 142. 
1.3 Immune defense against L. pneumophila infection 
As an accidental pathogen typically residing and replicating within freshwater 
protozoans there has been no selection pressure on L. pneumophila to establish 
mechanisms to evade the mammalian immune system. Nevertheless 
L. pneumophila is perfectly adapted to an intracellular life style also within alveolar 
macrophages since they share many features with amoeba, Legionella’s natural 
host. Within these alveolar macrophages L. pneumophila is then well hidden and 
protected from a broad range of immune defense strategies.  
1.3.1 Innate immunity to L. pneumophila infection 
After infection, L. pneumophila is recognized by several transmembrane and 
cytosolic pattern recognition receptors that cooperatively mediate protective 
immune responses 144. The transmembrane Toll-like receptors (TLRs) 2, -5, and -9 
detect bacterial cell wall components, flagellin and unmethylated CpG-rich DNA, 
respectively 145–149. These TLRs stimulate the production of several NF-B-
dependent cytokines such as TNF which contribute to resistance of mice towards 
L. pneumophila infection 150–153. Several studies demonstrated that mice deficient 
in TLR2 and the other above mentioned TLRs alone or in different combinations 
have defects in the defense against L. pneumophila compared to wild-type 
mice 146,147,150,153–155. The cytosolic NOD-like receptors (NLRs) NOD1 and NOD2 
are activated by Legionella peptidoglycan that might get access to the cytosol 
through the T4SS, and mice deficient in both NLRs or in the shared signaling 
mediator RIP2 show impaired neutrophil recruitment and attenuated bacterial 
clearance during pneumonia 156,157.  
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Other cytosolic sensors of L. pneumophila in macrophages are the canonical NAIP5 
and NLRP3 inflammasomes and the non-canonical caspase-11-dependent 
inflammasome. Different alleles of NAIP5 have long been known to determine 
whether a mouse is resistant or (moderately) susceptible to Legionella 
infection 158,159. NAIP5 forms together with the NLR molecule NLRC4 the NAIP5 
inflammasome, which can additionally contain the adapter molecule ASC and 
caspase-1 160–164. This multi-protein complex is activated by T4SS-mediated 
translocation of flagellin and mediates growth restriction of wild-type but not 
flagellin-deficient L. pneumophila in macrophages of most mouse strains (e.g. 
C57BL/6). This is dependent on the caspase-1-mediated cell death called pyroptosis 
and on enforcement of the phagolysosomal pathway leading to an enhanced fusion 
of LCVs with lysosomes 164–168. Another canonical inflammasome that is activated 
by L. pneumophila and additionally controls IL-1 and IL-18 production consists 
of NLRP3, ASC and caspase-1, although its function in controlling infection in vivo 
might be less important 169,170. Furthermore, L. pneumophila stimulates a cytosolic 
non-canonical caspase-11-dependent inflammasome depending on its 
T4SS 141,169,171. The exact mode of action of this inflammasome and its molecular 
components are ill-defined. Upon L. pneumophila infection of macrophages, the 
caspase-11 inflammasome contributes to the NLRP3 inflammasome-mediated 
IL-1 production and cell death, and stimulates a NLRP3-independent cell death 
and IL-1release 141,169,171. Moreover, caspase-11 has been indicated to stimulate 
fusion of LCVs with lysosomes 172. Thus, different inflammasomes are important 
mediators of the macrophage-intrinsic defense against L. pneumophila. 
The innate immune response to L. pneumophila is further shaped by translational 
inhibition and biasing to favor production of some proinflammatory 
mediators 173,174. This translational regulation is dependent on the T4SS and 
possibly on some effector proteins and/or on an effector protein-independent 
inhibition of the mTOR pathway 174.  
The function of neutrophils in Legionella infection is incompletely understood. 
Recruitment of neutrophils to the lung during infection is dependent on TLR- and 
NOD1/2-dependent chemokine production 156, and on release of IL-1 as well as 
IL-1 by hematopoietic cells 175, activation of IL-1R and production of chemokines 
by non-hematopoietic cells 176. Legionella spp. appear to be resistant to neutrophilic 
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killing 177,178, but antibody-mediated depletion of neutrophils impairs clearance of 
L. pneumophila from the lung at later time points 52. This might be related to 
production of cytokines such as IL-18 by neutrophils which together with IL-12 
activate NK cells to produce the host protective type II IFN (IFN53,151. IFN 
activates macrophages to restrict L. pneumophila replication and mice lacking IFN 
or  its  receptor  IFNGR  are  highly  susceptible  towards  L. pneumophila  
infection 179–181. Yet, the identity of the responsible antibacterial factors and their 
modes of action in L. pneumophila infection are still unknown (Figure 1.4). 
Besides neutrophils and NK cells, pDCs have been demonstrated to make important 
contributions to the restriction of L. pneumophila infection in mice 182. These cells 
were recruited during infection, and depletion of pDCs significantly reduced 
bacterial clearance from the lung. Interestingly, although pDCs are well known for 
their ability to produce type I IFNs upon viral infection, the protective effect of 
pDCs on L. pneumophila infection is independent of these cytokines 182. 
1.3.1.1 Production of type I IFNs in L. pneumophila infection 
In addition to the above mentioned pathways, L. pneumophila infection of 
macrophages is also detected by the recognition of bacterial nucleic acids in the 
host cell cytosol, and restricted by subsequently produced type I IFNs (Figure 1.4). 
It has previously been shown that host cells infected with L. pneumophila produce 
type I IFNs 183,184. This response requires bacterial uptake and expression of the 
bacterial T4SS, but is independent of bacterial replication and the IcmS-dependently 
translocated bacterial effector proteins 183–185. Although the sensor molecule is still 
unknown, several lines of evidence suggest that bacterial DNA is the molecule that 
is detected in the host cell cytosol and triggers type I IFN production. First, 
intracellular delivery of purified Legionella DNA into macrophages stimulates a 
similar type I IFN production as infection with viable bacteria 184,185. Second, 
type I IFN responses to L. pneumophila are dependent on the T4SS, and the T4SS 
has been shown to conjugate DNA to recipient bacteria 186. Third, digestion of 
Legionella extracts with DNAse (but not RNAse or proteinase) inhibited their 
ability to induce IFN expression 184,185. Fourth, the expression of the T4SS effector 
molecule SdhA negatively correlates with both, Legionella DNA release into the 
host cell cytosol and type I IFN responses 187–189. Fifth, L. pneumophila-induced 
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type I IFN production is significantly reduced in macrophages after gene-silencing 
of STING 185. STING is an ER-anchored molecule that serves as a key adapter 
protein for most cytosolic DNA sensing pathways 190,191. These cytosolic DNA 
sensor molecules include cyclic-AMP-GMP synthase (cGAS), DAI, IFI16, DDX41 
and RNA polymerase III/RIG-I 66,192–196. While DAI is not involved 197, and the 
function of RNA polymerase III/RIG-I is controversial 189,193 the role of the other 
DNA sensors in L. pneumophila-induced type I IFN responses needs to be 
examined.
 
Figure 1.4 Overview of innate immune defense mechanisms against L. pneumophila with focus 
on type I and II IFNs, as well as the NAIP5/NLRC4-inflammasome. See text for detail. 
In addition to DNA, detection of other bacterial molecules might contribute to 
stimulation of type I IFN responses during L. pneumophila infection. For example, 
Legionella second messenger molecules such as the cyclic dinucleotide c-di-GMP 
might also be involved in triggering STING-dependent innate immune responses, 
as STING also serves as receptor for c-di-GMP and c-di-AMP 198,199. Indeed, a 
recent study found that the amount of IFN expression in macrophages positively 
correlated with c-di-GMP levels in L. pneumophila 200. Moreover, one study 
indicated that recognition of Legionella RNA by the cytosolic RNA receptors RIG-I 
and MDA5 stimulated type I IFN response in macrophages 189. Downstream of the 
sensor and adapter molecules, the kinase TBK1 and the transcription factor IRF3 
are required for stimulating type I IFN responses to L. pneumophila 183,184.  
1.3 Immune defense against L. pneumophila infection 
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1.3.1.2 Function of type I IFNs in L. pneumophila infection 
The first evidence for a host-protective function of type I IFNs in L. pneumophila 
infections came from a study showing that IFN treatment inhibited growth of 
L. pneumophila in permissive murine A/J macrophages. Furthermore, addition of 
inhibitory anti-IFN antibodies allowed bacterial growth in otherwise restrictive 
cells 201. Subsequently, it was shown that inhibition of IRF3 expression by RNAi, 
and thus suppression of type I IFN production, resulted in enhanced L. pneumophila 
replication in human cells. The enhanced bacterial replication in IRF3-depleted 
cells could be reversed by treatment of the cells with exogenous IFN 183. Similarly, 
mouse macrophages deficient in IRF3 or IFNAR allowed bacterial replication, 
whereas wild-type macrophages from C57BL/6 mice inhibited wild-type 
L. pneumophila replication 185,202,203. These studies together show that 
endogenously produced type I IFNs act in an autocrine/paracrine fashion to activate 
a macrophage-intrinsic antibacterial defense pathway that restricts L. pneumophila. 
Importantly, recombinant IFN inhibited the growth of flagellin-deficient 
Legionella in wild-type macrophages, indicating that the type I IFN-mediated 
antibacterial defense acts independently of the flagellin-detecting NAIP5 
inflammasome 185. Whereas activity of both pathways (NAIP5, type I IFN) 
efficiently suppresses bacterial replication, functional defects in either pathway 
allow for substantial growth of L. pneumophila in macrophages. 
The mechanism of the type I IFN-mediated cell-autonomous resistance pathway is 
still incompletely understood but appears to act after LCV establishment, as it does 
not interfere with the trafficking of the LCV 185. Recent results further indicate that 
the type I IFN-mediated resistance pathway affects bacterial numbers in replication 
vacuoles by activating bacterial killing 185. This pathway most likely involves the 
IFN-stimulated GTPase IRGM1 and other genes that are type I IFN-dependently 
up-regulated in L. pneumophila-infected cells 185.  
During intranasal infection of mice with L. pneumophila flaA, type I and II IFNs 
appear to play a partly redundant role. Whereas mice deficient for the IFNGR have 
impaired bacterial clearance from the lung compared to wild-type mice, mice 
lacking type I IFN signaling show no defect 185. Importantly, however, mice lacking 
receptors for both type I and II IFNs have a strongly enhanced bacterial load after 
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infection as compared to mice lacking IFNGR only 185. Moreover, type I and II IFNs 
contribute to expression of IFN-stimulated genes in the lung during infection. 
Whereas some genes are dependent on either type I or II IFNs, others such as 
IRGM1 are regulated by both types of IFNs 185. Although further investigations are 
required, it appears reasonable to assume that both types of IFNs stimulate defense 
against L. pneumophila through expression of antibacterial acting proteins that 
possibly locate to the LCV. Considering the partly redundant effects of the 
type I and II IFNs on L. pneumophila infection in vivo, these antibacterial acting 
proteins are possibly induced by both types of IFNs although IFN may have a 
stronger inducing activity. 
1.3.2 Adaptive immunity to L. pneumophila 
First evidence for a relevant role of adaptive immune mechanisms in defense 
against L. pneumophila came from studies with T cell depleted mice 204. Here it was 
observed that in untreated wild-type mice, pulmonary clearance of L. pneumophila 
occurred not before T cell recruitment into the lungs, and depletion of CD4+ and 
CD8+ T cells impaired bacterial clearance and increased mortality 204. Another 
study showed that mice were protected from a lethal dose of L. pneumophila when 
they, prior to infection, received DCs overexpressing the T cell chemoattractant 
CX3CL1 (Fractalkine) and pre-incubated with heat-killed L. pneumophila. This 
was completely abolished when CD4+ and CD8+ T cells as well as B cells were 
depleted 205. One important role of CD4+ T cells might be the production of IFN. 
IFN levels increase dramatically upon infection 204 and bone marrow-derived DCs 
and macrophages were able to stimulate IFN production in CD4+ T cells 
in vitro 206,207. However, a main source of IFN in L. pneumophila infection might 
be NK cells 53.  
Besides T cell mediated mechanisms also B cell derived antibody responses seem 
to be important, since L. pneumophila-induced antibody production and increased 
clearance of antibody-opsonized L. pneumophila were reported 208,209. Furthermore, 
it was demonstrated that antibody-opsonized L. pneumophila are phagocytosed via 
a Fc receptor-dependent pathway leading to lysosomal degradation of the bacteria, 
a mechanism that subverts L. pneumophila’s evasion of the phagolysosomal 
fusion 210. 
1.4 Aim of this study 
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1.4 Aim of this study 
Upon infection, many intracellular pathogens establish characteristic membrane-
bound compartments within macrophages, where they resist lysosomal 
degradation 12,211. Such specialized vacuoles provide a growth niche with access to 
cellular nutrients while protecting the bacteria from humoral immune responses. As 
a result of co-evolution, however, host cells have developed sophisticated strategies 
to target the vacuoles or the bacteria inside in order to control infections 82,212. IFNs 
are among the most potent stimulators of those cell-autonomous resistance 
mechanisms. Yet, the molecular mechanisms of the IFN-induced, macrophage-
intrinsic antibacterial defense pathways remain incompletely understood.  
The aim of the present study was the systematic examination of the IFN-dependent 
antibacterial innate immune response to L. pneumophila infection by a combination 
of transcriptome and subcellular quantitative proteome analyses using in vivo, 
ex vivo and in vitro infection models. 
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2.1 Type I and II IFNs are key regulators of early gene expression 
in L. pneumophila infection in vivo 
In order to identify master regulators of the innate immune response to intracellular 
bacteria, gene expression in the lungs of L. pneumophila-infected and sham-treated 
C57BL/6 wild-type (WT) mice was compared 2 days post infection (d p.i.). 1526 
genes were found to be induced upon infection. To find the upstream regulators 
capable of inducing these genes, an upstream regulator analysis using Ingenuity 
Pathway Analysis (IPA) was performed (Figure 2.1a). This analysis predicts that 
type I and II IFNs and their related transcription factors such as STAT1 play a 
predominant role in controlling early gene transcription in response to 
L. pneumophila infection (Figure 2.1b). This in silico prediction was confirmed by 
transcriptome analysis of L. pneumophila-infected Ifnar-/-, Ifngr-/- and Ifnar/Ifngr-/- 
mice, all of which showed a severely impaired transcriptional response compared 
to WT animals (Figure 2.1c). 
 
Figure 2.1 Type I and II IFNs are key regulators of the early gene expression during 
L. pneumophila infection in vivo. (a) Overview of the workflow for upstream regulator analysis 
depicted in (b). (b) WT mice were intranasally infected with 1 × 106 L. pneumophila wt or treated 
with PBS. Mice were sacrificed on day 2 p.i., total RNA was isolated from whole lungs and mRNA 
microarray analysis was performed. Genes found to be significantly up-regulated (> 2-fold change, 
p < 0.05) in L. pneumophila infected WT mice compared to PBS controls were analyzed for their 
predicted upstream regulators using Ingenuity Pathway Analysis (IPA). Black bars highlight 
molecules with established functions in type I and/or type II IFN signaling. (c) WT, Ifnar-/-, Ifngr-/- 
and Ifnar/Ifngr-/- mice were intranasally infected with 1 × 106 L. pneumophila wt or treated with 
PBS. Mice were sacrificed on day 2 p.i., total RNA was isolated from whole lungs and mRNA 
microarray analysis was performed. Heatmap displays the 1526 genes significantly up-regulated in 
L. pneumophila-infected compared to PBS-treated WT mice. (5 mice per group, pooled for RNA 
isolation; ratio of infected versus PBS-treated mice for respective strain is depicted). 
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2.2 Type I and II IFNs mediate antibacterial immunity during 
L. pneumophila infection in the lung  
To investigate the relevance of the type I and II IFN pathways individually and in 
combination for their role in antibacterial defense against L. pneumophila, bacterial 
clearance following L. pneumophila infection of WT, Ifnar-/-, Ifngr-/- and 
Ifnar/Ifngr-/- mice was analyzed. Whereas WT, Ifnar-/- and Ifngr-/- mice were able 
to clear or strongly reduce bacterial burdens by day 6 p.i., bacterial loads remained 
high in Ifnar/Ifngr-/- mice (Figure 2.2a). This persistently high pulmonary bacterial 
load in Ifnar/Ifngr-/- mice was accompanied by high neutrophil counts in the blood 
and lung (Figure 2.2b, c).  
 
Figure 2.2 Type I and II IFNs mediate host-protective immune response during 
L. pneumophila infection in vivo. WT, Ifnar-/-, Ifngr-/- and Ifnar/Ifngr-/- mice were intranasally 
infected with 1 × 106 L. pneumophila wt or treated with PBS. Mice were sacrificed on day 2, 4 or 
6 p.i. and bacterial loads in lungs were determined (dotted line indicates lower detection limit) (a). 
Neutrophils in the blood (b, percent of total leukocytes) and in the lung (c, percent of total lung cells) 
were determined by flow cytometry (b) and manual differentiation of May-Grünwald-Giemsa-
stained cytospin preparations from lung homogenates (c), respectively. Data represent mean + s.e.m. 
of 5-6 mice per group. * p<0.05, ** p<0.01, *** p<0.001 (Kruskal-Wallis analysis of variance 
followed by two-tailed Mann-Whitney U test with Bonferroni correction for multiple comparisons 
(a) or Dunn’s multiple comparison (b,c)). 
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The continuing neutrophil influx led to highly inflamed lung tissue in those animals 
after infection with either L. pneumophila wt or flaA (Figure 2.3a). Defective 
innate host defense and exacerbated pneumonia were further evidenced by a 
continued weight loss in Ifnar/Ifngr-/- mice until day 8 p.i. with L. pneumophila wt 
or flaA (when most likely an effective adaptive immune response is initiated) 
(Figure 2.3b, c). All other mice (WT, Ifnar-/-, Ifngr-/-) exhibited early bodyweight 
loss, probably reflecting the acute inflammatory response, but rapidly recovered 
their bodyweight after infection. Together, these data indicate that type I and 
type II IFNs are critical regulators of the early gene expression and the antibacterial 
innate immune response during L. pneumophila infection.  
 
Figure 2.3 Lack of type I and II IFN signaling results in highly inflamed lung tissue and 
delayed but prolonged bodyweight loss during L. pneumophila infection in vivo. WT, Ifnar-/-, 
Ifngr-/- and Ifnar/Ifngr-/- mice were intranasally infected with 1 × 106 (a) or 1 × 107 (b, c) 
L. pneumophila wt or flaA. (a) Mice were sacrificed 6 d p.i. and histopathology of lungs was 
analyzed by hematoxylin and eosin staining (representative images of 4 mice per group, scale bar 
indicates 2 mm). (b, c) Bodyweight of infected mice was determined over time. Data represent 
mean + s.e.m. of 10 mice per group. * p<0.05, ** p<0.01, *** p<0.001 (two-way ANOVA followed 
by Bonferroni posttest). 
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2.3 An alveolar macrophage-intrinsic antibacterial defense 
pathway is activated by IFNs to restrict L. pneumophila 
infection 
Alveolar macrophages, but not dendritic cells (DCs), are thought to be the primary 
cell type supporting L. pneumophila infection in vivo 213–215. To test whether the 
protective role of IFNs during L. pneumophila infection was mediated at the level 
of an alveolar macrophage-intrinsic defense pathway, a mouse model in which IFN 
signaling was selectively abrogated in alveolar macrophages and DCs, which both 
express CD11c was examined (Figure 2.4).  
 
Figure 2.4 Overview of the generation of mixed bone marrow chimeric mice and the 
subsequent diphtheria toxin (DTX) mediated depletion of CD11c+ DTR-GFP expressing cells. 
To this end CD45.1+ mice were lethally irradiated and reconstituted with a 1:1 
mixture of CD45.2+ bone-marrow cells from Ifnar/Ifngr-/- and CD11c-DTR-GFP 
mice (expressing the diphtheria toxin receptor (DTR) under the control of the 
CD11c   promoter).   Repopulation   was   assessed   to  be  >   90%   after  10  weeks 
(Figure 2.5a). Treatment with diphtheria toxin (DTX) depleted CD11c+ GFP+ DTR-
expressing cells in the lung (Figure 2.5b), generating mice in which all CD11c- cell 
types express the type I and II IFN receptors, whereas only CD11c+ cells (alveolar 
macrophages and DCs) were unresponsive to IFNs. First, only bone-marrow-
chimeric mice which showed highly efficient DTX-mediated depletion of CD11c+ 
GFP+ DTR-expressing cells (with < 10% remaining, Figure 2.5c) were examined. 
Strikingly, chimeric mice lacking the IFN receptors in CD11c+ cells were unable to 
clear L. pneumophila wt infection (Figure 2.5d), phenocopying mice lacking IFN 
signaling in all cell types (Figure 2.2a), whereas bacterial burdens were reduced in 
the control animals. Second, when analyzing all mice repopulated with 
Ifnar/Ifngr -/- and CD11c-DTR-GFP cells including those showing a weak depletion 
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of CD11c+ GFP+ cells (Figure 2.5c), a significant negative correlation between 
remaining CD11c+ GFP+ cells (expressing IFN receptors) and pulmonary bacterial 
load was observed (Figure 2.5e). Given that dendritic cells do not support 
L. pneumophila growth 213,214, these data strongly suggest that IFNs directly activate 
Legionella-containing alveolar macrophages to restrict intracellular infection. 
 
Figure 2.5 Type I and II IFNs restrict L. pneumophila infection through a cell-intrinsic 
mechanism within CD11c+ cells in the lung. CD45.1 recipient mice were lethally irradiated and 
repopulated with a 1:1 mixture of bone-marrow cells from CD45.2 transgenic CD11c-DTR-GFP 
and Ifnar/Ifngr-/- or WT donor mice. (a) Repopulation with CD45.2 donor cells within CD45.1 
recipient mice was assessed by flow cytometry of whole lung cells (representative dot plot). (b, c) 
diphtheria toxin (DTX) mediated depletion of CD11c+ GFP+ DTR-expressing cells was assessed by 
flow cytometry of whole lung cells (representative dot plots). (c) Total CD11c+ (CD45+ CD11c+) 
cells were further differentiated in macrophages/monocytes (CD45+ CD11c+ SiglecF+/CD64+) and 
dendritic cells (CD45+ CD11c+ CD64- SiglecF- MHC-IIhi). Only mice with < 10% GFP+ (of all 
CD11c+ cells) were considered for analysis depicted in (d). (d) Bacterial load of mixed bone marrow-
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chimeric mice was determined after infection with L. pneumophila wt (4-7 mice per group, dotted 
line indicates lower detection limit). (e) Frequency of remaining CD11c+ GFP+ cells was correlated 
to bacterial load in the lungs of CD11c-DTR-GFP / Ifnar/Ifngr -/- + DTX chimeric mice including 
all DTX-treated mice (13 mice). * p<0.05, ** p<0.01, *** p<0.001, Kruskal-Wallis analysis of 
variance, Dunn’s multiple comparison (d), Pearson correlation (e).  
To further analyze the IFN-driven antibacterial mechanism, primary alveolar 
macrophages from WT, Ifnar-/-, Ifngr-/- and Ifnar/Ifngr-/- mice were isolated and 
purity confirmed by flow cytometry analysis (Figure 2.6a).  
In line with the conclusion that the IFN-dependent effect observed in vivo relies on 
alveolar macrophages, L. pneumophila flaA, which is able to replicate in B6 WT 
alveolar macrophages due to evasion of the NAIP5/NLRC4-mediated 
restriction 164,165,167,168, is partly or completely, respectively, inhibited by IFN or 
IFN treatment (Figure 2.6b). Conversely, Ifnar-/- and Ifnar/Ifngr-/- alveolar 
macrophages supported replication of otherwise growth-restricted L. pneumophila 
wt (Figure 2.6c). These data indicate that endogenously produced type I IFNs 
control bacterial growth, whereas type II IFN is not relevant in this ex vivo model 
since alveolar macrophages hardly produce IFN (data not shown). Collectively, 
these data strongly suggest that L. pneumophila infection is controlled by an IFN-
mediated alveolar macrophage-intrinsic mechanism. 
 
Figure 2.6 Primary alveolar macrophages restrict L. pneumophila replication upon activation 
by IFNs. Alveolar macrophages of WT, Ifnar-/-, Ifngr-/- and Ifnar/Ifngr-/- mice were isolated and 
checked for purity by flow cytometry (a); numbers adjacent to outlined areas indicate percent cells. 
Cells were left untreated (c) or were treated with 50 U/ml IFN or IFN (b) 16-18 h prior to and 
during infection with L. pneumophila flaA (b) or wt (c). Bacterial growth was determined by CFU 
counting after 72 h. Data represent 3 independent experiments done in triplicates. * p<0.05, 
** p<0.01, *** p<0.001 (two-tailed Mann-Whitney U test). # No bacteria were detected 
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2.4 The IFN-mediated intracellular bacterial killing within 
macrophages is largely independent of cell death and inducible 
NO synthase 
To determine how macrophages restrict L. pneumophila upon activation by IFNs, 
bone marrow-derived macrophages (BMMs) were used, an easily available and 
frequently used cell model to study L. pneumophila infection 164,165,167,168,185,202. As 
shown in alveolar macrophages (Figure 2.6c), treatment of BMMs with IFN or 
IFN restricted the growth of L. pneumophila flaA (Figure 2.7a, b), which is in 
line with previous reports 185,202.  
Figure 2.7 Type I 
and II IFNs restrict 
L. pneumophila in 
bone marrow-derived 
macrophages. (a-c) 
Intracellular growth of 
L. pneumophila flaA in 
WT BMMs left untreated 
or treated with 
IFNIFN or both 
16-18 h prior to and 
during infection. (d) 
Intracellular growth of 
L. pneumophila wt and 
flaA in WT and Ifnar-/- 
BMMs. Data represent 
mean + s.e.m. of 2 (b), 
4 (c) or 5 (a, d) 
experiments done in 
triplicates. * p<0.05, 
** p<0.01, *** p<0.001, 
no indication if not 
significant (two-tailed 
Mann-Whitey U test), 
significance was tested 
against untreated control 
(a-c) or between wild-
type and knock-out cells 
for each condition (d). 
Importantly, treatment of BMMs with suboptimal doses of both cytokines alone or 
in combination resulted in comparable growth inhibition (Figure 2.7c), suggesting 
that type I and II IFNs might activate a similar intracellular restriction mechanism. 
Moreover, lack of responsiveness to auto-/paracrine IFN in Ifnar-/- BMMs resulted 
in replication of otherwise growth-restricted L. pneumophila wt, and further 
enhanced the growth of L. pneumophila flaA (Figure 2.7d). 
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Figure 2.8 Type I and II IFNs restrict L. pneumophila in macrophages largely independent of 
cell death. Cell death of infected (GFP+) cells was analyzed by flow cytometry; the gating strategy 
is depicted (a; encircled numbers indicate gating order). Numbers adjacent to outlined areas indicate 
percent cells. (b, c) Cell death in bacteria-harboring (GFP+) WT and Ifnar-/- BMMs upon infection 
with L. pneumophila wt or flaA expressing eGFP analyzed by LIVE/DEAD staining and flow 
cytometry. Representative blots (b) and summarized results (c) of 4 experiments done in tricplicates 
are shown. (d, e) Cell death in bacteria-harboring (GFP+) WT IFN-treated BMMs (d), and Rip3-/- (e) 
BMMs infected with L. pneumophila wt or flaA expressing eGFP was determined by flow 
cytometry. Data represent mean + s.e.m. of 2 (e) or 4 (c, d) experiments done in triplicates. * p<0.05, 
** p<0.01, *** p<0.001, no indication if not significant (two-tailed Mann-Whitey U test), 
significance was tested against untreated control (d) or between wild-type and knock-out cells for 
each condition (c, e). 
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In order to assess whether IFNs restrict L. pneumophila growth by inducing cell 
death, e.g. via caspase-11-dependent pyroptosis or RIP3-dependent 
necroptosis 135,171, cell viability of BMMs infected with L. pneumophila was 
measured. To determine viability exclusively in cells that are infected and thus 
harbor bacteria, a flow cytometry based approach using GFP-expressing 
L. pneumophila was established (Figure 2.8a). Cell death in infected cells was 
minimally  affected  by  IFN  treatment  (Figure 2.8d),  or  by  the  lack  of  IFNAR 
(Figure 2.8b, c) or RIP3 (Figure 2.8e). As expected, however, infection with 
L. pneumophila wt enhanced cell death compared to flaA as a consequence of 
NAIP5/NLRC4/caspase-1-dependent pyroptosis 164,167,168 (Figure 2.8c, e). 
 
Figure 2.9 Type I and II IFNs restrict L. pneumophila in macrophages independently of RIP3, 
caspase-11 and iNOS. Intracellular growth of L. pneumophila wt and flaA in WT, Rip3-/-, 
Casp11-/- and Nos2-/- BMMs left untreated or treated with IFN, IFNor both 16-18 h prior to and 
during infection. Data represent mean + s.e.m. of 2 (a, b, d, e) or 3 (c, f) experiments done in 
triplicates. * p<0.05, ** p<0.01, *** p<0.001, no indication if not significant (two-tailed Mann-
Whitey U test), significance was tested against wild-type and knock-out cells for each condition. 
Furthermore, RIP3 and caspase-11 deficiency did not influence bacterial growth or 
its inhibition by IFNs at 24 and 72 h p.i. (Figure 2.9a, b, d, e). Another important 
restriction mechanism against intracellular bacteria is the production of NO via 
inducible NO synthase (iNOS) 130,131. However, L. pneumophila wt and flaA 
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replication and IFN-mediated bacterial clearance were comparable in WT and 
iNOS-deficient (Nos2-/-) macrophages (Figure 2.9c, f). Thus, neither cell death nor 
production of reactive nitrogen species by iNOS appears to be critical for the IFN-
mediated control of L. pneumophila infection. 
2.5 Subcellular quantitative proteomics reveal that type I and II 
IFNs markedly modify the vacuolar protein composition 
Based on previously published data 185 and the results shown above, it was 
hypothesized that IFNs target antibacterial effector proteins to the LCV to restrict 
the bacterial replication inside. In order to identify putative IFN-regulated effectors 
in an unbiased manner, the LCV proteome of untreated and IFN-treated 
macrophages was examined (Figure 2.10). 
 
Figure 2.10 LCVs from untreated and IFN-treated BMMs are isolated and their protein 
composition analyzed by quantitative label-free proteomics in order to identify putative IFN-
regulated effector molecules. 
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To this end, untreated and IFN- or IFN-treated BMMs were infected with 
L. pneumophila flaA (to prevent NAIP5-mediated restriction), LCVs were 
enriched by immuno-affinity separation and density gradient centrifugation 216,217 
(Figure 2.11a, b), and analyzed by label-free quantitative mass spectrometry. 
 
Figure 2.11 Schematic overview (a) and immunofluorescence images (b) of single steps of the 
immuno-affinity separation and subsequent density gradient centrifugation to isolate LCVs. 
Encircled numbers from (a) correspond to respective images in (b). (b) LCVs harboring red 
fluorescent L. pneumophila flaA (red) were visualized by staining for SidC (green), a 
L. pneumophila effector protein that localizes to the surface of LCVs. Contaminating DNA and cell 
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debris were visualized by DAPI staining (blue) and differential interference contrast microscopy 
(grey), respectively. LCVs from infected BMMs were enriched in the eluate of immune-affinity 
separation and were further purified in fraction 4 after density gradient centrifugation (scale bar 
indicates 5 µm). 
2854 proteins were identified in 6 of 6 samples from LCVs of untreated 
macrophages at a false-discovery rate (FDR) < 1%, 2307 derived from the host and 
547 from the bacterium (Figure 2.12a). Computed gene ontology (GO) enrichment 
analysis of all identified host proteins for cellular components revealed the highest 
significance values for the GO terms ‘membrane-bounded organelle’ 
(p = 1 × 10-305) and ‘intracellular membrane-bounded organelle’ (p = 3.55 × 
10-300). As expected 12,22, further evaluation revealed highest significance values for 
the ‘mitochondrion’ (p = 2.38 × 10-296), ‘endoplasmic reticulum’ (p = 7.08 × 10-100) 
and ‘vacuole’ (p = 9.67 × 10-62) as predicted child terms of ‘intracellular 
membrane-bounded organelle’ (Figure 2.12b).  
 
Figure 2.12 Proteomic analysis of LCVs from untreated BMMs infected with L. pneumophila 
flaA. (a) 2854 proteins were detected in all six replicates of which 2307 were identified as host- 
and 547 as L. pneumophila-derived. (b) GO enrichment analysis for overrepresented cellular 
components of the host proteins was done and overrepresented child terms of GO:0043231 
‘intracellular membrane-bounded organelle’ were extracted. Depicted are p-values for the indicated 
GO terms as well as the number of identified proteins annotated with each term; # no p-value for 
GO term ‘nucleus’ was computed. 
Additional GO enrichment analyses of biological processes indicated an enrichment 
of proteins involved in metabolic (e.g. ‘glucose catabolic process’, ‘tricarboxylic 
acid cycle’ and ‘fatty acid metabolic process’), and transport and localization 
processes (e.g. ‘ER to Golgi vesicle-mediated transport’ and ‘actin cytoskeleton 
organization’) (Figure 2.13). 
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Figure 2.13 Proteins involved in metabolic processes and transport and localization are 
strongly enriched at LCVs. GO enrichment analysis of the 2,307 host proteins identified in 
untreated LCV samples for biological processes using BiNGO (Cytoscape). Hierarchical structure, 
read from inside (first node, blue encircled) to outside (final nodes, pink encircled). Subnetworks of 
highly enriched biological functions are highlighted (metabolic process, transport/localization, 
biological regulation, immune system process) and GO terms mentioned in the text are indicated by 
green and yellow triangles. Significance cut-off value for visualization was set to 10-10, ancestor 
terms with p > 10-10 are depicted if final child term had p-value < 10-10. 
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Next, LCV proteins from IFN- or IFN-treated BMMs were compared to vacuolar 
proteins from untreated cells as well as to each other. Treatment with either IFN did 
not change the abundance of LCV marker proteins like ARF1, RAB1 and SEC22b, 
or ER marker proteins such as calreticulin and calnexin, nor did it lead to an 
enrichment of endosomal or lysosomal proteins like RAB5, RAB7, vacuolar 
ATPases and LAMP1 (Table 2-1). These data are in line with previously published 
data 185 and indicate that IFNs do not affect the trafficking of the LCV or its general 
composition of ER-derived material. 
Table 2-1 Fold change in abundance of selected host proteins upon IFN-treatment identified 
by mass spectrometry on purified LCVs. 
 
 IFNβ/untreated IFNγ/untreated 
LCV marker 
ARF1 1,7 1,7 
RAB1a 1,3 1,1 
RAB1b 1,0 1,1 
SEC22b 1,1 1,0 
ER marker 
Calreticulin 1,0 1,1 
Calnexin 1,2 1,2 
endosome marker 
RAB5a 1,8 1,8 
RAB5b 1,5 1,7 
RAB5c 1,6 1,7 
RAB7a 1,2 1,2 
RAB7b 1,2 1,1 
endosome/lysosome 
vATPase subunit A 1,0 1,1 
vATPase subunit C1 0,9 1,0 
vATPase subunit G1 1,0 1,2 
lysosome marker 
LAMP1 0,7 0,7 
Cathepsin B 0,4 0,4 
Myeloperoxidase 0,6 0,7 
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However, IFN or IFN treatment led to a significant (p < 0.05) vacuolar 
enrichment (> 2-fold) of 260 or 321 proteins, respectively, and to a 
decreased (< 0.5-fold) vacuolar abundance of 60 or 67 proteins (Figure 2.14a-f). 
The direct comparison between LCV proteomes from IFN- or IFN-treated cells 
revealed rather minor differences with many proteins being similarly regulated and 
only few, although distinct, proteins being differentially affected (Figure 2.15a-c). 
For example, RSAD2, GBP2 and IFIT1 were the three proteins with the strongest 
enrichment at the LCV upon both, IFN and IFN treatment (Figure 2.14d, f). 
Proteins that differed significantly between IFN- and IFN-treated samples 
included proteins involved in MHC class II-dependent antigen presentation 
(e.g. H2-AB1, H2-AA). Those MHC class II-associated proteins were 
preferentially regulated by type II IFN (Figure 2.15b, c, Figure 2.16). 
 
Figure 2.14 Type I and II IFNs alter the protein composition of LCVs. Quantitative proteomic 
analysis of LCVs from BMMs left untreated or treated with 50 U/ml IFNor IFN16-18 h prior to 
infection with L. pneumophila flaA. (a, b) Volcano plots show proteins with a significant higher 
(red) or lower (green) abundance at LCVs from IFN- (a) or IFN- (b) treated BMMs compared to 
untreated cells (LFQ = label free quantity; LFQ intensity ratio = fold change). (c-f) List of proteins 
with highest change upon IFN (c, d) or IFN (e, f) treatment compared to untreated samples. 
Proteomic analysis was done from 6 (untreated), 5 (IFN) and 4 (IFN) individual LCV isolations. 
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Figure 2.15 LCV proteomes from IFN- or 
IFN-treated cells reveal few but distinct 
differences in protein abundance. 
Quantitative proteomic analysis of LCVs from 
BMMs left untreated or treated with 50 U/ml 
IFNor IFN16-18 h prior to infection with L. 
pneumophila flaA. (a) Volcano plot shows 
proteins with a significantly different abundance 
at LCVs from IFN- and IFN- treated BMMs 
compared against each other (LFQ = label free 
quantity; LFQ intensity ratio = fold change). (b, 
c) List of proteins with higher abundance in 
IFN- (b) or IFN- (c) treated samples. 
Proteomic analysis was done from 5 (IFN) and 
4 (IFN) individual LCV isolations. 
Next, all proteins found to be enriched 
IFN-dependently at the LCV were 
analyzed using the database STRING 
(http://string-db.org), which integrates 
known and predicted protein 
interactions from different sources. This 
analysis generated a dense network of 
protein interactions, with many proteins 
being involved in immune response 
processes (Figure 2.16). These proteins 
included molecules contributing to 
DNA/RNA detection (e.g. TMEM173 
[also known as STING], TLR3), ubiquitinylation/ISGylation (e.g. ISG15, 
TRIM25), antimicrobial defense (e.g. IRGM1, IRGM2, GBP2, GBP7, NRAMP1, 
IRG1), antigen processing/presentation, and the proteasome complex. Finally, the 
list of IFN-dependently LCV-enriched proteins was compared with the 
INTERFEROME database of IFN-regulated genes 218 as well as own transcriptome 
data. Importantly, this analysis revealed distinct subsets of IFN-regulated proteins 
(Figure 2.16). Whereas several LCV-enriched proteins are also transcriptionally 
induced by IFNs and thus represent bona fide ISGs, others such as Psmc1-6 or 
Psmd1-3 are not directly transcriptionally regulated but appear spatially affected by 
IFNs. Taken together, these data demonstrate that IFNs markedly modify the 
protein composition of LCVs, and that some of the proteins targeted to the vacuole 
might be spatially, rather than directly transcriptionally, regulated by IFNs. 
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Figure 2.16 Integrated network analysis of IFN-regulated proteins of the LCVs. Proteins with 
higher abundance at LCVs from IFN- and/or IFN-treated compared to untreated cells were 
analyzed with the STRING database. The proteome data were further compared with the whole 
genome microarray data (compare Figure 2.1c; > 2-fold higher expressed in infected WT vs. 
Ifnar/Ifngr-/- mice) and the INTERFEROME database to indicate molecules which are also 
transcriptionally regulated by IFNs. A GO enrichment analysis was performed for extracting 
significant subnetworks of a complex network composed of 335 nodes and 2,612 edges. Shown are 
subnetworks positively affected by IFN and/or IFN activation such as ‘immune response’, 
‘antigen processing and presentation’ and the ‘proteasome complex’. 
2.6 IRG1 restricts L. pneumophila replication within the vacuole 
 
45 
2.6 IRG1 restricts L. pneumophila replication within the vacuole 
Next, it was assessed whether the proteins identified by quantitative proteomics as 
enriched at the LCV upon IFN treatment were involved in restricting bacterial 
growth. Considering the partly redundant functions of type I and II IFNs in 
restricting L. pneumophila infection (Figure 2.2a, Figure 2.7c), analyses particular 
focused on proteins that were most strongly targeted to the LCV by both types of 
IFNs. BMMs were first transfected with a pool of two siRNAs for each of the 
candidate molecules as well as IFNAR1 as a control, and efficient gene silencing 
was verified (Figure 2.17a). It was found that silencing the expression of IRG1 
enhanced replication of L. pneumophila wt to a similar extent as silencing of 
IFNAR1 and thereby the entire type I IFN signaling (Figure 2.17b). Silencing 
THEMIS2, GBP3 and GBP7 also augmented the bacterial growth of 
L. pneumophila to some extend compared to control siRNA, while the other tested 
candidates had no effect.                                              
 
Figure 2.17 siRNA based screen of candidate proteins targeted IFN-dependently to the LCV 
identifies IRG1 as crucial IFN-driven effector molecule. BMMs were transfected with control 
siRNA or a pool of two specific siRNAs per gene 24 h prior to infection. Knock-down efficiency 
was assessed by qRT-PCR 24 h p.i. (a) and numbers of bacteria were determined by CFU counting 
72 h p.i. (b). Data are mean + s.e.m. of 2 (a) or 4 (b) independent experiments done in triplicates. 
* p<0.05, ** p<0.01, *** p<0.001, no indication if not significant (two-tailed 
Mann-Whitney U test). 
In order to confirm the location of IRG1 at the LCV microscopic analyses of cells 
overexpressing IRG1 were conducted. A previously reported mitochondria-like 
distribution of IRG1 119 could be confirmed (data not shown, Figure 2.18a, d), and 
a close association with the LCV was demonstrated (Figure 2.18a, b).  
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Figure 2.18 IRG1 associates with LCVs, and restricts replication of L. pneumophila within 
macrophages. Ifnar-/- BMMs overexpressing IRG1-GFP (a, b, d) or GFP only (c) were infected 
with DsRed-expressing L. pneumophila wt (red). (a, b) 2 h p.i. cells were fixed (a) or homogenized 
and fixed (b) and LCVs and nuclei were visualized by SidC (LCV-located L.pneumophila-protein; 
cyan) and DAPI (blue) staining, respectively. Details from upper left are shown as z-stack and as 
single channels for depicted x-y-plane. (c-e) Cells were fixed 24 h p.i. and intracellular bacteria were 
counted (e). Scale bars indicate 5 µm. (e) 150-250 GFP- / IRG1-GFP-expressing cells were counted, 
data represent mean + s.e.m. of 2 independent experiments. 
Importantly, overexpression of IRG1 in Ifnar-/- cells, which express only little 
amounts of endogenous IRG1 upon L. pneumophila infection (data not shown), 
markedly decreased intracellular growth of L. pneumophila wt as compared to 
control-transfected Ifnar-/- cells. This was indicated by a lower percentage of IRG1-
expressing macrophages harboring >10 bacteria and a higher percentage of cells 
harboring only one bacterium inside (Figure 2.18c-e). These data demonstrate that 
IRG1 is regulated by IFNs, localizes to the LCV, and restricts intracellular 
replication of L. pneumophila within macrophages. 
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2.7 IRG1 restricts L. pneumophila through production of the 
antibacterial metabolite itaconic acid  
IRG1 is a newly characterized mitochondrial protein which has recently been 
implicated in the production of mitochondrial ROS (mROS) as well as the 
metabolite itaconic acid, and in antibacterial defense in macrophages 121,127. To 
assess whether mROS is IRG1- and IFNAR-dependently produced in 
L. pneumophila infected cells, BMMs were infected with GFP-expressing 
L. pneumophila to measure mROS production by flow cytometry. It was found that 
mROS is produced in infected cells by a largely IRG1- and IFNAR-independent 
mechanism (data not shown), thus arguing against a major role of mROS in IRG1-
mediated restriction of L. pneumophila.  
 
Figure 2.19 IRG1 restricts L. pneumophila through production of the antibacterial metabolite 
itaconic acid. (a-c) Intracellular levels of itaconic acid were measured by GC/MS in WT BMMs 
18 h post stimulation with 50U/ml IFN or IFN (a) or 24 h post infection with L. pneumophila wt 
(m.o.i. 10) in cells left untreated (b) or transfected with control siRNA or IRG1-siRNA (c). 
(d) Indicated concentrations of itaconic acid were added to L. pneumophila in liquid culture and 
OD600 was determined over time to assess bacterial growth. 
Next, the production of itaconic acid was examined. Treatment of macrophages 
with type I and II IFNs as well as infection with L. pneumophila strongly stimulated 
the production of itaconic acid (Figure 2.19a, b), whereas gene-silencing of IRG1 
largely reduced the production of this metabolite (Figure 2.19c). Importantly, 
itaconic acid dose-dependently inhibited L. pneumophila growth in liquid culture 
(Figure 2.19d) at a physiological concentration 121. Thus it seems that IRG1 restricts 
L. pneumophila through catalyzing the production of the antibacterial metabolite 
itaconic acid. 
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2.8 IRG1 restricts L. pneumophila in alveolar macrophages and 
IFN-dependently produces itaconic acid in vivo 
In order to assess the role of IRG1 in antibacterial defense in primary cells alveolar 
macrophages from WT mice were isolated. Importantly, knock-down of IRG1 
expression  by  specific  siRNAs  significantly  increased  bacterial  replication 
(Figure 2.20a, b). It was further found that IRG1 was IFN-dependently expressed 
in vivo in mouse lungs upon L. pneumophila infection (Figure 2.20c) resulting in 
an IFN-dependent itaconic acid production (Figure 2.20d).  
 
Figure 2.20 IRG1 restricts replication of L. pneumophila within primary alveolar macrophages 
and is regulated by IFNs in vivo. (a, b) Alveolar macrophages were transfected with control siRNA 
or a pool of two IRG1-specific siRNAs 24 h prior to infection. Knock-down was assessed by 
qRT-PCR 24 h p.i. (a) and CFUs were counted 72 h p.i. (b). (c, d) WT, Ifnar-/-, Ifngr-/- and 
Ifnar/Ifngr-/- mice were infected with L. pneumophila wt, treated with PBS or left untreated. 2 d p.i.. 
Irg1 expression (c) and itaconic acid production (d) were determined by qRT-PCR and GC/MS, 
respectively. (a, b) Data are mean + s.e.m. of 3 independent experiments done in quadruplicates. 
* p<0.05, ** p<0.01, *** p<0.001, (two-tailed Mann-Whitney U test). (c, d) Data represent 
mean + s.e.m. of 5 (c) and 4 (d) mice per group.  
Together with the initial findings that Ifnar/Ifngr-/- mice are severely impaired in 
controlling L. pneumophila infection (Figure 2.2a) and that IFN signaling is of 
particular importance in CD11c+ cells (Figure 2.5d), these data suggest that 
L. pneumophila replication in alveolar macrophages in vivo is restricted by 
IFN-regulated IRG1 producing itaconic acid. 
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3.1 Summary 
Several different PRRs, including TLR2, -5 and -9, NOD1 and -2, NAIP5/NLRC4 
as well as yet-to-be identified cytosolic nucleic acid sensors are well known to 
contribute to the early detection of L. pneumophila. Recognition via these receptors 
initiates a complex network of signaling cascades, including NF-B- and IRF3/7-
dependent pathways. This finally leads to dramatic transcriptional changes within 
infected cells, and via the induction of a wide variety of cytokines also within 
uninfected neighboring cells and whole tissues and organs in general. The relative 
importance of individual cytokines and signaling pathways for these global 
transcriptional changes are, however, largely unknown. Furthermore, while the 
relevance of single signaling pathways and cytokines for the outcome of 
L. pneumophila infection are at least to some extent reported, the exact molecular 
effector mechanisms underlying the final restriction of the pathogen are less clear. 
The present study uncovers that type I and II IFNs together are the master regulators 
of the early pulmonary transcriptional response to L. pneumophila infection. While 
the lack of one system could partially be compensated by the other system, the lack 
of both signaling pathways results in tremendous defects in gene expression and 
leads subsequently to the loss of the capability to control the infection. This 
type I and II IFN-driven host-protective effect is shown here to rely on CD11c+ 
cells, which are most likely alveolar macrophages. Activation of macrophages by 
IFNs leads to substantial changes of the protein composition of the Legionella-
containing vacuole (LCV), the place where L. pneumophila replicates. The reported 
changes are to a great extent overlapping between both types of IFNs, 
demonstrating the partial redundancy of both systems. These protein composition 
changes involve proteins which are also transcriptionally regulated by IFNs and are 
therefore bona fide ISGs. Surprisingly, also proteins that are not IFN-dependently 
influenced in their mRNA expression are, however, IFN-dependently targeted to 
the LCV. This spatially regulation of proteins is a hitherto unrecognized mechanism 
of action mediated by IFNs. Among proteins that are IFN-dependently targeted to 
the LCV, IRG1 was identifies as a crucial antibacterial effector molecule. Since 
IRG1 was previously reported to localize to mitochondria, which are long known 
to closely associate with the LCV, IRG1 could be induced by IFNs and localize to 
the LCVs together with mitochondria. IRG1 exerts its antimicrobial force via the 
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production of itaconic acid, a metabolite found here to efficiently block 
L. pneumophila growth at concentrations previously measured in activated murine 
macrophages.  
 
Figure 3.1 Overview of the IFN-mediated host protection against L. pneumophila via IRG1-
derived antibacterial itaconic acid. See text for details. 
In conclusion, the present study demonstrates the high relevance of a macrophage-
intrinsic IFN-driven cell autonomous defense mechanism against L. pneumophila 
in vivo. Furthermore, it provides for the first time comprehensive insight into the 
transcriptional and spatial regulations induced by type I and II IFNs that lead to 
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critical modifications in the proteome of bacterial vacuoles, and it identifies a novel 
IFN-controlled defense pathway against L. pneumophila infection which relies on 
the IRG1-dependent production of the antimicrobial metabolite itaconic acid. 
3.2 IFNs – master regulators of the alveolar macrophage intrinsic 
defense in vivo 
Several different innate immune mechanisms have been shown to contribute to the 
defense against L. pneumophila in vivo, including TLR-dependent TNF 
production 150–153,155, NOD1/2-dependent neutrophil recruitment 156, 
NLRC4/caspase-1 dependent pyroptosis 162 and the production of IL-1 by 
hematopoietic cells 175. Furthermore, an important role for the type II IFN IFN in 
L. pneumophila defense 179–181, as well as a strong induction of type I IFNs in 
L. pneumophila infected cells have been reported 183–185. Finally it was shown, that 
the infection of human monocyte-derived macrophages and primary human lung 
tissue with L. pneumophila led to dramatic transcriptional changes 219,220, whereas 
the key regulators and the individual importance of different signaling pathways for 
these changes remained unknown. Here it was found that the tremendous 
transcriptional  changes  observed  upon  L.  pneumophila  infection  in  vivo   
(Figure 2.1a, c) are in large part regulated by the concerted action of 
type I and II IFNs (Figure 2.1b, c). Besides the remarkable importance of 
type I and II IFNs, cytokines like TNF, IL-1 and IL-18 as well as the transcription 
regulator NF-kB were predicted in silico to be involved in regulation of pulmonary 
gene expression, which is in line with previous studies, reporting a contribution for 
these factors in defense against L. pneumophila 151,157,173,175.  
The striking inability of mice lacking both IFN receptors to control L. pneumophila 
infection compared to WT and single knock-out mice (Figure 2.2a, Figure 2.3a) is 
in line with previous findings 185, and underlines the importance of both IFNs for 
the antibacterial defense. It also demonstrates the potential to compensate the lack 
of only one of both receptors by signaling via the other receptor. This is most likely 
explained by the induction of many ISGs by both types of IFNs, and, accordingly, 
due to partially overlapping and redundant patterns of gene expression induced by 
type I and II IFNs 83. 
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While innate immune mechanisms and especially IFNs are crucial to control the 
early defense against L. pneumophila, they might be dispensable during the later 
phase of infection (Figure 2.3b, c). The late but distinct onset of recovery of mice 
deficient in both IFN receptors at 7 to 8 d p.i. might be explained by the initiation 
of an efficient adaptive immune response at this stage of infection. It was reported, 
that IgA antibody titers in the BAL fluid of intranasally L. pneumophila infected 
mice started to rise at day 7 p.i. and increased during the following days 209. A 
second report showed that antibody-opsonized and therefore FcR-dependently 
phagocytosed L. pneumophila are unable to evade the phagosolysosomal fusion and 
killing 210. It is thus tempting to speculate that an efficient antibody production 
combined with an altered phagocytosis might contribute to bacterial clearance at 
later stages of infection. Further studies addressing these questions might compare 
bacterial clearance in IFNAR- and IFNGR-deficient mice left untreated or treated 
with antibodies to block the FcR or to deplete antibody-producing B cells. 
Alveolar macrophages are the primary target and host cells of L. pneumophila in 
men and experimentally infected mice. But which cell type is responsible for an 
efficient control and final elimination of L. pneumophila in an IFN-dependent and 
also -independent way? Neutrophils were found here to be recruited into the lung 
of L. pneumophila infected mice and their numbers increase especially in 
Ifnar/Ifngr -/- mice over time, correlating with consistently high pulmonary bacterial 
load in these animals (Figure 2.2c). This clearly shows that the lack of IFN signaling 
does not interfere with neutrophil recruitment and that neutrophils in these mice are 
apparently insufficient to control the infection. This might be due to the previously 
described resistance of Legionella spp. to neutrophil-mediated killing 53,178. On the 
other hand, neutrophils were reported to be required for efficient clearance of 
L. pneumophila from the lung 52,53. Neutrophils therefore seem to be involved in 
defense against L. pneumophila rather indirectly via immunomodulatory effects 
through their secreted cytokines 52,53 than through a direct antibacterial mechanism. 
The data shown here demonstrate that IFNs activate macrophages to restrict 
L. pneumophila infection (Figure 2.6a-c, Figure 2.7a-d). Furthermore, 
IFN signaling in CD11c+ cells is indispensable for control of L. pneumophila 
infection in vivo (Figure 2.5d, e). Since DCs do not support L. pneumophila 
replication 182,213,214, the findings presented here indicate that IFNs mediate their 
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host protection by activating a cell-intrinsic antibacterial mechanism in alveolar 
macrophages. This idea is further supported by the finding that IFNs also activate 
primary alveolar macrophages ex vivo to restrict L. pneumophila replication  
(Figure 2.6a-c). 
While type II IFN is well-known for its activation of antibacterial immunity to most 
intravacuolar bacteria, type I IFNs have been shown to either enhance or inhibit 
those responses 86. The present study shows that type I IFNs are protective during 
L. pneumophila infection, which is in line with previous reports 185,201. One could 
speculate that the differential roles of type I IFNs in various bacterial infections 
might be explained by differences in the relative contribution of IFN-dependent 
defense systems versus other intracellular or extracellular immune mechanisms. 
3.3 It’s neither cell death nor iNOS - then what? 
IFNs can execute their antimicrobial functions via several different mechanisms, 
including the induction of cell death and the production of RNS 82. Yet, both of 
these mechanisms have been shown here to have no major impact on IFN-mediated 
host defense against L. pneumophila (Figure 2.8a-e, Figure 2.9a-f).  
IFN-driven cell death has been shown to occur during infections with several 
intracellular pathogens, however, this had rather detrimental consequences for the 
host 133. In S. Typhimurium infection the IFNAR-dependent necroptosis was shown 
to rely on the activation of RIP3 kinase 135,136. But, while macrophages infected 
with L. pneumophila underwent flagellin-dependent and –independent cell death as 
previously reported 164,167,168, the L. pneumophila-induced cell death in 
macrophages was neither influenced by treatment with recombinant IFN or IFN 
nor by the lack of IFNAR (Figure 2.8b-d). Furthermore, since the lack of RIP3 
kinase did not affect cell death or intracellular replication of L. pneumophila, a 
relevant role of necroptosis in IFN-mediated defense can be excluded (Figure 2.8e, 
Figure 2.9a, d). The recently identified non-canonical caspase-11 inflammasome 
can be regulated by type I IFNs, can mediate cell death, and its stimulation by 
L. pneumophila has been reported 140,141,169,171. Therefore, the involvement of 
caspase-11 in IFN-dependent cell-autonomous immunity against L. pneumophila in 
macrophages was tested. The data shown here demonstrate that caspase-11 is not 
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required for IFN-mediated defense against L. pneumophila (Figure 2.9b, e). Taken 
together, cell death seems to play no major role in IFN-dependent cell-autonomous 
resistance against L. pneumophila in macrophages. This is in line with the host-
protective role of both IFNs during L. pneumophila infection and the rather 
detrimental consequences of IFNAR-driven cell death in other intracellular 
bacterial infection models 133. 
RNS and particularly NO production by iNOS are known to be triggered by type I 
and II IFNs 128,129. Furthermore NO production has been reported to correlate with 
clearance of L. pneumophila in macrophages from mice and guinea pigs 221. 
However, the role of iNOS-mediated NO production for the control of 
L. pneumophila infection in vivo is controversial 131,179,222. The data presented here 
show that iNOS is dispensable for host-defense against L. pneumophila in both 
unstimulated and IFN-stimulated macrophages (Figure 2.9c, f). Moreover, although 
an IFNAR-dependent expression of iNOS upon L. pneumophila infection was 
observed (data not shown) and iNOS has been found to be largely enriched on latex-
bead phagosomes of IFN-activated macrophages 132, iNOS was undetectable on 
LCVs from either untreated or IFN-treated macrophages (data not shown). One 
could therefore speculate that L. pneumophila has evolved strategies to inhibit 
targeting of iNOS to the LCV to escape from NO-mediated killing, a strategy 
already described for M. tuberculosis 223,224. This idea might further be supported 
by the previous finding, that an avirulent strain of L. pneumophila led to the 
production of significantly more NO in murine macrophages than the virulent 
parental strain from which the avirulent strain was derived by multiple passages 221. 
Classical and long known IFN-driven defense mechanisms like cell death and RNS 
production were found to play no major role in IFN-mediated antibacterial defense 
against L. pneumophila. In contrast, it has recently been shown that the immunity-
related GTPases IRGM1 and IRGM3 are involved in the IFN-dependent host-
defense against L. pneumophila 115,185. Additionally, other reports showed that 
IRGM1 as well as other members of the large family of IFN inducible GTPases are 
targeted to pathogen-containing vacuoles and confer host-resistance against 
bacteria and parasites 109,112,225–228. Last but not least a recent report demonstrated 
the tremendous changes of the proteome composition of latex-bead phagosomes in 
macrophages upon IFNstimulation 132. These studies, together with the discussed 
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findings that IFNs stimulate an alveolar macrophage intrinsic defense mechanism 
against L. pneumophila stimulated the idea to apply a new approach here to further 
characterize the IFN-mediated antibacterial mechanism against L. pneumophila. By 
quantitative comparison of the proteome composition of untreated and IFN-treated 
macrophages, new IFN-driven effector molecules were identified (Figure 2.10, 
Figure 2.14d, f, Figure 2.17b). 
3.4 Legionella’s protected niche – not destroyed by IFNs, but 
heavily targeted 
After phagocytosis by macrophages, L. pneumophila employs a large arsenal of 
bacterial effector molecules to remodel its phagosome by recruitment of ER-
derived, ribosome-decorated vesicles and mitochondria to establish the 
LCV 12,13,22,23,26,229. Proteomic analyses of these LCVs from untreated macrophages 
shown here identify a high number of host proteins to be inside, on the surface of 
or in contact with the LCV (Figure 2.12a). In silico analyses of the cellular 
localization of these host proteins reveal a large subset of mitochondrial proteins as 
well as ER- and GOLGI-derived proteins (Figure 2.12b). This is in line with the 
current knowledge about the LCV biology and confirms recently published LCV 
proteome data from a murine macrophage cell line, showing mitochondrial proteins 
being the largest group of proteins at the LCV, followed by ER-derived proteins 217. 
Given the recruitment and possibly even fusion of entire mitochondria with the 
LCV compared to the recruitment of only ER-derived vesicles 22, it is not surprising, 
that mitochondrial proteins are almost 2-fold more enriched at the LCV than ER 
proteins (Figure 2.12b). Looking at the biological processes in which these proteins 
are known to be involved and thereby looking at their functions, it becomes clear 
that a distinct proportion of these proteins is involved in metabolic processes 
(Figure 2.13) which is in line with a previous study 217 and nicely reflects the 
association of mitochondria and ribosomes, organelles with high metabolic activity, 
with the LCV. Furthermore, the appearance of many proteins known to be involved 
in transport and localization processes (Figure 2.13) mirrors the high degree of 
ongoing remodeling of the initial phagosome driven by the pathogen to establish its 
protected niche, the LCV. The occurrence of a certain amount of proteins known to 
be involved in immune system processes, demonstrates that even in unstimulated 
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cells,  a  defense  response  against  the  invading  pathogen  is  initiated  rapidly 
(Figure 2.13). Together these data confirm the close association of the LCV with 
mitochondria and the ER and identify the LCV as place of high metabolic activity. 
Comparing the LCVs from untreated and IFN-treated macrophages, it becomes 
clear that fundamental characteristics of the LCV structure are not influenced, as 
indicated by equal abundance of well-established LCV and ER marker proteins 
(Table 2-1). Importantly, neither endosomal nor lysosomal marker proteins increase 
at the LCV upon IFN-stimulation, clearly demonstrating that IFNs do not force 
phagolysosomal fusion. This finding is in accordance with published data showing 
no enhanced LAMP-1 (lysosomal marker) or reduced calnexin (ER marker) 
staining of LCVs from IFN treated versus untreated cells 185. On the other hand, 
activation of macrophages with type I and II IFNs leads to the vacuolar targeting of 
hundreds of proteins, while only few proteins show reduced vacuolar abundance 
upon IFN stimulation (Figure 2.14a, b). Notably, the direct comparison between 
both types of IFNs reveals only minor differences in the vacuolar proteome changes 
stimulated by each IFN individually (Figure 2.15a). This further supports the idea 
that type I and II IFNs stimulate similar or largely overlapping effector mechanisms 
against L. pneumophila. Computed network and GO-enrichment analyses reveal 
that many proteins targeted to the LCV upon IFN stimulation are involved in 
diverse aspects of immune response mechanisms (Figure 2.16). This subgroup of 
proteins includes several proteins known to be involved in nucleic acid detection 
(e.g. STING [Tmem173], TLR9, TLR3, RIG-I [Ddx58], MDA5 [Ifih1], LGP2 
[Dhx58]), a process well known to be a vital part of innate defense against 
L. pneumophila 183–185,189. Furthermore, SLC15A3 was found to enrich at the LCV 
upon IFN stimulation (Figure 2.16). SLC15A3 was recently found to localize to 
endosomes and mediate the egress of bacteria-derived products which can then be 
sensed on the cytosolic side of the phagosomal membrane 230. IFNs might thus 
enhance the expression and vacuolar localization of proteins involved in pattern 
recognition and enhance transport of bacteria derived molecules into the cytosol to 
improve bacterial detection.  
Another study analyzed the role of NLRP3-driven caspase-1 activation in 
phagosome acidification. It was reported that active caspase-1 enriches on bacteria-
containing phagosomes and locally controls the pH by modulating the NADPH 
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oxidase NOX2 231. Likewise, caspase-1 was found here to be localized at the LCV 
and this is enhanced by both IFNs (Figure 2.16). Furthermore, NLRP3 is enriched 
at the LCV upon IFN treatment (Figure 2.16). Finally also NOX2 is abundant at 
the LCV (data not shown). Since additionally to NLRP3 also NAIP5/NLRC4 
stimulation, which is highly relevant in L. pneumophila infection, activates 
caspase-1 a caspase-1-mediated control of the pH within the LCV should be 
addressed in further studies.  
Among immune response-related proteins, proteins with reported antimicrobial 
effector functions form the largest subgroup. This includes proteins with known 
antiviral functions like RSAD2 (also known as viperin) 98 and SAMHD1 232,233 as 
well as proteins acting antibacterial or antiparasitic like IRGM1 185,228,234, 
GBP2 111,226, GBP7 112, NRAMP1 235 and IRG1 121,127. Given the already described 
IFN-dependent expression and phagosomal/vacuolar localization of some of these 
proteins (e.g. IRGM1, GBP2, GBP7) 105,225, it might be not surprising to find them 
on LCVs from IFN-activated macrophages. One could argue that this reflects the 
IFN-driven expression of these proteins followed by an unspecific targeting to all 
kinds of phagosomes, including the LCV. A finding strongly arguing against this 
simplistic view is that other ISGs known to localize to bacteria-/parasite-containing 
vacuoles and found also on latex-bead phagosomes from IFN activated 
macrophages, like GBP1 and iNOS 112,132,223,225, were undetectable at LCVs from 
IFN-treated and untreated cells. This might be explained by a pathogen-mediated 
inhibition of vacuolar targeting of these proteins, as described for iNOS on 
M. tuberculosis-containing phagosomes 223,224. Alternatively the phagosomal 
targeting of those proteins might be tightly controlled by the host cell and might 
differ depending on the phagocytosed content. Additionally, some proteins 
identified on the LCV, including RSAD2 and IRG1 have not been previously found 
on bacteria-containing vacuoles or latex-bead phagosomes upon 
IFNtreatment 119,132. Instead, they were described to localize to cellular organelles 
such as the ER or mitochondria 98,119. While this could further support the idea of a 
content-dependent phagosomal targeting, it might also reflect differences in the 
phagosome architecture. The proteome of latex bead phagosomes contains only 
3 - 4% mitochondrial proteins 236, in contrast mitochondrial proteins account for 
almost one third of the LCV proteins (Figure 2.12a, b). Thus, especially 
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mitochondrial and ER-located ISGs enrich at the LCV, which is known to associate 
with mitochondria and to fuse with ER-derived vesicles 22. 
3.5 Spatial protein regulation – a new mode of action of IFNs  
Interestingly, the comparison of IFN-directed vacuolar proteins with the 
INTERFEROME database of known ISGs as well as own transcriptome data 
uncovers a large subset of proteins showing an IFN-dependent vacuolar targeting 
without any apparent IFN-dependent transcriptionally regulation (Figure 2.16). 
This suggests that IFNs are able to control the spatial distribution of a subset of 
proteins, a previously unrecognized mode of action of IFNs. Interesting examples 
of this spatial protein regulation include, but are not limited to, proteins from the 
proteasome complex (Figure 2.16). Although they are not known to be IFN-
dependent transcriptionally regulated, they were found here to accumulate at the 
LCV upon stimulation with IFNand/or IFN.  
Another group of proteins, which is quite interesting in this context, are proteins 
involved in MHC-I/II dependent antigen processing and presentation. Several of 
which localize to the LCV in an IFN-driven fashion. Many of those proteins are 
known ISGs (Figure 2.16) and were also reported to enrich on latex bead 
phagosomes in IFN-activated macrophages 132. The data presented here show for 
the first time that proteins involved in MHC class I and II antigen presentation are 
also targeted to bacterial vacuoles by IFNs. However, while IFN treatment leads 
to the accumulation of MHC-I- and -II-related molecules, IFN treatment targets 
primarily MHC class I antigen presentation-related molecules to the LCV. This is 
in line with the important functions of both, type I IFNs and MHC-I, in antiviral 
immunity. However, according to the INTERFEROME database both types of IFNs 
can potentially regulate most of these molecules transcriptionally, although levels 
of induction might differ. Nevertheless, the differential abundance of MHC-I and -II 
proteins at the LCV might further point towards a transcriptionally independent 
spatial regulation by IFNs, which would in this case be a negative regulation. 
Potential mechanisms of such a positive or negative spatial protein regulation might 
involve the induction, activation or maybe even suppression of signaling molecules 
that control recruitment and localization of certain proteins by IFNs. Interestingly, 
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a previous study reported that IFN treatment influences both, the abundance as 
well as the phosphorylation status of several phagosomal proteins 132, the latter of 
which might affect their signaling properties and cellular localization. In line with 
this idea, several proteins involved in protein phosphorylation and 
dephosphorylation such as the protein-tyrosine kinases SYK, BTK, HCK and LYN 
as well as the protein phosphatases PPM1H, PPP2CA and PPP2R2A are enriched 
on LCVs upon IFN treatment (Figure 2.16). Furthermore, IFNs increase the 
abundance of molecules involved in phosphatidylinositol signaling such as 
PIP4K2C and PI3KAP1. Phosphatidylinositol phosphates (PIPs) are long known 
regulators of membrane trafficking and provide binding sites for a wide variety of 
proteins on membranes 237. Modifying these PIPs can therefore lead to distinct 
changes in the membrane protein composition. This newly identified and hitherto 
unreported spatial regulation of proteins by IFNs represents an interesting new 
mechanism of action of IFNs and should be addressed in more detail in further 
studies.  
3.6 IRG1 is a key effector molecule against L. pneumophila  
After exploring the IFN-driven changes in protein abundance at the LCV in general, 
single IFN-dependent LCV-targeted proteins were analyzed for their individual role 
in host defense against L. pneumophila (Figure 2.17). This includes proteins 
showing the strongest quantitative increase in vacuolar abundance driven by both 
IFNs (Figure 2.14d, f). Additionally, proteins highly enriched at the LCVs upon 
IFN treatment but undetectable on LCVs from unstimulated cells (e.g. GBP3, 
GBP5) were selected. While several of these candidate-proteins showed no impact 
on intracellular bacterial growth, the knock-down of some proteins led to a 
significant increase in L. pneumophila replication, suggesting a role in antibacterial 
defense.  
Most importantly, IRG1 was found to most strongly inhibit L. pneumophila in 
macrophages. Knock-down of IRG1 affected the bacterial growth to a similar extent 
as inhibition of IFNAR1 expression (Figure 2.17, Figure 2.20a, b). While this strong 
phenotype of IRG1 knock-down could mean that the entire type I IFN-mediated 
antibacterial defense relies on IRG1, it is more likely that it reflects possible 
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differences in the efficiency of the siRNA-mediated knock-down. While knock-
down efficiency for IRG1 and IFNAR1 were comparable on mRNA level, 
differences might occur on protein level. IRG1 is expressed at very low levels at 
steady state, but strongly induced upon infection. siRNA transfection prior to 
infection might thus efficiently prevent translation of infection-induced mRNA into 
the IRG1-protein. In contrast, IFNAR1 is expressed constitutively at high levels 
and although mRNA levels appear to be low upon siRNA treatment, the IFNAR1 
protein might still be present to some extend due to the protein turnover time. An 
alternative explanation might include the previously reported findings indicating 
that IRG1 is induced also by other stimuli including several proinflammatory 
cytokines like IFN, TNF and IL-1 as well as different bacteria and 
LPS 118,119,126,238. IRG1 might therefore still be expressed to some extend when 
IFNAR1 is knocked down, which was observed here in IFNAR-deficient mice 
(Figure 2.20c).  
The data presented here are the first to show that IRG1 localizes to bacterial 
vacuoles in activated macrophages. Interestingly, IRG1 was not detected on latex-
bead phagosomes from IFN-treated macrophages 132, although it is induced by 
IFN as reported previously 119 and indicated by own data. One out of several 
differences between latex bead phagosomes and LCVs is that only the latter are 
known to co-localize with mitochondria 22,26. The proteome data of untreated LCVs 
confirm this previous observation and reveal a high content of mitochondrial 
proteins associated with the LCV (Figure 2.12), possibly derived from entire 
mitochondria that attached to and therefore co-purified with the LCVs. IRG1 is 
considered to be a mitochondrial protein 119. The mitochondria-localized protein 
IRG1 might hence indirectly be targeted to the LCV together with mitochondria. 
IRG1 was shown recently to mediate defense against S. Typhimurium potentially 
by two different mechanisms 121,127 and mechanisms relevant for IRG1-mediated 
defense against L. pneumophila are discussed below.  
Besides IRG1 also knock-down of the IFN-inducible GTPases GBP3 and GBP7 
was found here to result in a less pronounced but significant increase in 
L. pneumophila replication (Figure 2.17). Together with GBP1, GBP2 and GBP5 
these proteins are encoded on chromosome 3 of the mouse genome. It was recently 
demonstrated that mice lacking this region of chromosome 3 encoding for GBP1, 
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GBP2, GBP3, GBP5 and GBP7 were defective in the IFN-mediated host defense 
against T. gondii, 113. However, while re-expressing GBP7 partially restored the 
IFN-driven protection against T. gondii, re-expression of GBP3 showed no 
effect 113. Furthermore, another study found an important role of GBP7 in IFN-
mediated defense against L. monocytogenes and M. bovis BCG, probably by 
regulation of oxidative killing and delivery of antimicrobial peptides, while knock-
down of GBP3 had no effect 112. Hence, the data presented here add to the 
knowledge about GBP7´s function in antimicrobial innate immunity and are the 
first to suggest a role of GBP3 in host defense against intracellular pathogens. 
THEMIS2 is a further protein whose inhibition by siRNA leads to increase in 
L. pneumophila replication (Figure 2.17). THEMIS2 was identified as a scaffold 
protein involved in regulation of TLR signaling and cytokine production, and 
shown to be up-regulated by LPS and IFN 239. It has, however, not yet been 
implicated in antibacterial defense. Taking the described role in regulation of TLR 
signaling and cytokine production into account, the potential effect of THEMIS2 
on antibacterial defense might be rather indirect. 
Several of the IFN-dependently LCV targeted proteins were found here in a siRNA-
based screen to potentially contribute to the IFN mediated defense against 
L. pneumophila. However, siRNA based approaches might lead to unspecific off-
target effects and thus to false positive results. Further studies should therefore 
address the validation of the findings reported here, by applying different siRNAs 
individually, making use of possibly already existing knock-out cells or by applying 
the rapidly emerging technique of CRISPR/CAS9 mediated gene silencing 240.  
3.7 The key effector is a mitochondrial protein - are mitochondria 
at the LCV then blessing or curse for the pathogen? 
Mitochondria have long been known to co-localize or even attach to LCVs as well 
as other microbe-containing vacuoles 22,241–244. In T. gondii infection, a pathogen-
mediated recruitment of mitochondria to the parasitophorous vacuole has been 
described and pathogen-derived effector proteins involved in this process were 
identified 242,244. For Legionella, the mechanism underlying mitochondrial 
recruitment and attachment, and most importantly, their biological function at the 
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LCV remain, however, largely unknown. Although a Legionella-derived 
chaperonin was proposed to induce mitochondria recruitment, this has only been 
shown for latex-beads and all attempts to generate a L. pneumophila strain with a 
deletion of the encoding gene failed 245. To date at least two L. pneumophila-derived 
proteins were identified to be targeted to mitochondria. The first protein was 
reported to be involved in sphingoine-1 phosphate metabolism, but its role in 
Legionella pathogenesis remains elusive 246. Another study found that 
L. pneumophila secretes a mitochondrial carrier protein (LncP) through its T4SS 
which assembles within the mitochondrial inner membrane and transports ATP 
unidirectional across membranes 247. Thus, L. pneumophila might actively recruit 
the mitochondria as a source of energy or nutritional metabolites. 
Alternatively, mitochondria might be actively targeted to the LCVs by the host cell, 
as indicated by a recent report 248. This report showed that mitochondria localize to 
phagosomes that contain bacteria or TLR agonists via a TLR-, TRAF6-, and 
ECSIT-dependent mechanism. This study further indicated that mitochondrial ROS 
production was crucial for defense against Salmonella infection 248. Furthermore, 
mitochondria also contain several molecules involved in pattern recognition such 
as MAVS 249,250 together with further molecules involved in downstream signaling 
(e.g. TOM70, TRIM14) 251,252 as well as STING 253. Additionally, release of 
mitochondrial DNA upon infection induced stress was found to trigger type I IFN 
responses via the cGAS-STING-IRF3 axis 254, a process which is tightly counter-
regulated by apoptotic caspases in dying cells to protect from overwhelming 
inflammatory responses 255,256. Thus, mitochondria might act as platforms for 
diverse innate immune functions to defend against intravacuolar and other 
pathogens, and similar mechanisms were described already in plants 257. 
Many bacterial toxins are known to target to mitochondria and modulate their 
functions. However, whether this targeting aims to inhibit defense mechanisms or 
to provide the pathogen with mitochondria-derived nutrients is in most cases less 
clear 258. Two studies shedding some light on these questions identified bacterial 
proteins from L. monocytogenes and V. cholera that modify the dynamics of 
mitochondria in order to interfere with mitochondria-mediated immune 
mechanisms against these pathogens 259,260. Remarkably, it was recently reported 
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that bacterial targeting of mitochondria is surveyed by the host and leads to the 
initiation of innate immune responses in Caenorhabditis elegans 261. Thus, 
mitochondria appear to be central organelles in the host-pathogen interaction and 
antimicrobial defense.  
In L. pneumophila infection, it is not yet clear whether mitochondria are actively 
recruited to the LCV by the pathogen itself or targeted to the vacuole by the host. 
In an unstimulated infected cell, mitochondria might possess some benefit during 
the early phase of infection, when many of the immunity-related mitochondrial 
proteins are not expressed or only at low levels. Up-regulation of those proteins in 
an ongoing infection might lead to rather detrimental effects of the mitochondria 
for L. pneumophila at later time points and mitochondria were found to disappear 
from the LCVs 4-8 h post infection 22. One could speculate that this is driven by L. 
pneumophila in order to evade immune effector mechanisms carried out by 
mitochondrial proteins that are up-regulated during the infection process, however 
there is so far no experimental evidence for this hypothesis. In contrast, in a pre-
stimulated cell, e.g. by paracrine acting IFNs, mitochondrial proteins that target the 
pathogen, e.g. IRG1, are expressed already at high levels and the early recruitment 
of mitochondria to the LCV leads to restriction of the infection. In case of a TLR-
mediated recruitment of mitochondria to the LCV and other pathogen-containing 
vacuoles the concomitant IFN-dependent up-regulation of antimicrobial molecules 
within this organelle might therefore represent a combined two-step strategy of the 
immune system to counteract intravacuolar pathogens.  
3.8 It’s all about metabolism – bacteria are restricted by a host 
derived metabolite 
The mitochondrial protein IRG1 was identified here as highly enriched at the LCV 
in response to IFN stimulation, and importantly, as being a major restriction factor 
for L. pneumophila. IRG1 has recently been shown to exhibit antibacterial activity 
against the intracellular pathogen S. Typhimurium and two different mechanisms 
were proposed 121,127. Two reports indicated an involvement of IRG1 in ROS 
production, with one of them finding an IRG1-mediated regulation of -oxidation-
dependent mitochondrial ROS production important for bacterial killing 126,127. 
However, a contribution of IRG1 to mROS production during L. pneumophila 
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infection was not found here (data not shown). In contrast, another study identified 
IRG1 as an enzyme catalyzing the decarboxylation of the tricarboxylic acid (TCA) 
cycle metabolite cis-aconitate to itaconic acid 121,262, which is long known to inhibit 
bacterial growth under certain conditions 122. Itaconic acid was initially described 
and for a long time thought to be a metabolite produced only by fungi 263. Only 
recently it has been identified also within mammalian macrophages, where it was 
produced upon stimulation with LPS and might also be secreted 262,264,265. 
Moreover, metabolic profiling of M. tuberculosis-infected mice also found itaconic 
acid to be produced in vivo 266. A central role of IRG1 and its product itaconic acid 
in activated macrophages has been further evidenced recently. Integrating parallel 
metabolomic and transcriptomic data from polarized macrophages the authors 
found IRG1 and itaconic acid to be among the most strongly up-regulated genes 
and metabolites, respectively, in M1 macrophages. Furthermore, the entire TCA 
cycle in M1 polarized macrophages appeared to be redirected in order to provide 
substrates for itaconic acid synthesis by IRG1 267. In line with these previous 
findings, itaconic acid is produced by macrophages upon stimulation with IFN or 
IFN, as well as during L. pneumophila infection in an IRG1-dependent manner 
in vitro (Figure 2.19a-c). Strikingly, pulmonary IRG1 expression as well as 
pulmonary itaconic acid level are both strongly enhanced upon L. pneumophila 
infection in vivo and both highly depend on IFN signaling (Figure 2.20c, d).  
As mentioned above, itaconic acid is known to inhibit different bacterial species 
including Pseudomonas indigofera, S. enterica, M. tuberculosis and Yersinia pestis 
when growing on minimal media with either acetate or fatty acids as limiting carbon 
source 121–123. This was found to be due to the inhibition of the isocitrate lyase (ICL), 
an enzyme of the glyoxylate shunt which is essential for the survival of bacteria 
when growing on fatty acids or acetate 121,123,262. Itaconic acid also efficiently 
inhibits the growth of L. pneumophila (Figure 2.19d). Interestingly, this appears not 
to require a restriction of carbon sources since bacteria were grown on a rich 
medium containing yeast extract and thereby providing a wide range of different 
carbon sources. Moreover, it is thought that the glyoxylate shunt, which is blocked 
by itaconic acid in other bacteria is absent in L. pneumophila 268. So how does 
itaconic acid then inhibit L. pneumophila growth? L. pneumophila is well known to 
rely on amino acids as energy and carbon source when growing within host  
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cells 269–271. Itaconic acid was reported to inhibit another enzyme within bacteria, 
the propionyl-CoA carboxylase (PCC) 262,272. This enzyme is of high importance 
for the degradation of propionyl-CoA during the catabolism of the amino acids 
threonine, valine, isoleucine and methionine and is present from bacteria to 
humans 273. According to available genetic information, this enzyme is also present 
in L. pneumophila 274 and might therefore also be blocked by itaconic acid. Another 
way to degrade propionyl-CoA is the methylcitrate cycle. Catabolism of 
propionyl-CoA via this pathway is of high importance especially in bacteria, fungi 
and apicomlexa to protect from toxic concentrations of propionate 275–277. 
Moreover, for L. pneumophila and M. tuberculosis it was found that a defect in this 
pathway led to decreased intracellular replication and in the case of L. pneumophila 
also to faster bacterial killing 276,278. An inhibitory effect of itaconic acid on the 
methylcitrate cycle by inhibiting the methylisocitrat lyase (MCL) activity of ICL or 
direct inhibition of the MCL, an enzyme involved in the methylcitrate cycle, has 
been discussed 121,262, although experimental evidence is still missing. The 
degradation of propionyl-CoA as an intermediate of amino acid catabolism seems 
to be of particular importance and inhibition might lead to rapid intoxication by 
propionate. Taken together, itaconic acid might act antibacterial on L. pneumophila 
by blocking propionyl-CoA catabolism via inhibiting the PCC or the MCL. 
Furthermore, itaconic acid might inhibit also other yet-to-be-identified mechanisms 
in L. pneumophila. 
Besides direct growth inhibition of L. pneumophila and other bacteria an even 
broader application of itaconic acid might arise from a recent study demonstrating 
that ICL, which is blocked by itaconic acid, mediates broad tolerance against 
different antibiotics in M. tuberculosis 279. Thus, a combined antibiotic-itaconic 
acid-treatment might increase the antibacterial efficiency against multi-drug 
resistant pathogens. Finally, the particular importance of itaconic acid as an 
antimicrobial metabolite was recently further highlighted by a study demonstrating 
that many bacteria and especially pathogens possess three genes for degradation of 
itaconic acid 125,262. These genes had been known before to be crucial for the 
intracellular survival of some pathogens within macrophages, without knowing 
their exact function 125. Although homologs of these genes were also found for 
Legionella longbeachea, no information was given for L. pneumophila. 
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Furthermore it is not clear whether these genes are expressed in L. longbeachae and 
if this itaconic acid-degrading pathway is functional.  
3.9 Conclusion and Outlook 
Since its first identification in 1976 L. pneumophila has caused several large 
outbreaks of Legionnaires’ disease with high mortality rates, and has been more 
and more recognized as an important cause of community-acquired pneumonia. To 
meet the requirements of an efficient and targeted treatment of Legionella 
infections, it is of high importance to decipher the underlying mechanisms of an 
effective immune response. Understanding the molecular basis will help to develop 
more specific and therefore more efficient treatment strategies. Several previous 
studies addressed and identified different innate immune mechanisms being 
involved in antibacterial defense against L. pneumophila. The relative contributions 
of these individual pathways as well as the molecular mechanisms finally leading 
to the killing of the pathogens are however incompletely understood.  
The data presented here demonstrate that type I and II IFNs are critical regulators 
of the early gene expression and antibacterial immune response against 
L. pneumophila. This IFN-mediated immune defense relies on cell-intrinsic 
mechanisms within CD11c+ cells, most likely alveolar macrophages. Quantitative 
proteomic studies of the protein composition of the LCV, the place were 
L. pneumophila replicates, identifies several hundred proteins to be targeted to the 
LCV by IFNs. Interestingly, a large subset of those proteins are not transcriptionally 
regulated by type I or type II IFNs, which indicates a previously unrecognized 
spatial protein regulation by IFNs that should be addressed in further studies. 
Among the IFN-dependently LCV-targeted proteins, IRG1 was identified as crucial 
antibacterial effector molecule. IRG1 mediates the production of the metabolite 
itaconic acid to restrict L. pneumophila in macrophages. In times of increasing 
numbers of antibiotic resistant pathogens, new treatment options for bacterial 
infections are urgently needed. Further studies should therefore address itaconic 
acid´s potential as a therapeutic agent to treat L. pneumophila infections as well 
infections with other bacteria.
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4.1 Bacteria 
Bacteria stocks were kept at -80°C in in ACES-buffered yeast extract (AYE) broth 
(10 g/l ACES buffer, 10 g/l yeast, 0.4 g/l cysteine, 0.135 g/l ferric nitrate, pH 6.9) 
containing 50% glycerol. The L. pneumophila serogroup 1 strain JR32 280, the flaA 
mutant (ΔflaA) 162,168 and the corresponding strains constitutively expressing 
enhanced GFP or the red fluorescent protein DsRed 281 were cultured on buffered 
charcoal yeast extract (BCYE) agar 282 2 d for in vitro infections. ΔflaA mutants 
expressing eGFP or DsRed have been generated in this study by isolating the 
encoding plasmids from the respective wt strain 281 using a commercial available 
plasmid isolation kit and introducing the plasmids into the L. pneumophila JR32 
flaA mutant by electroporation 283. To maintain plasmids, chloramphenicol (cam) 
was added at 5 µg/ml to BCYE plates or AYE broth, respectively. For LCV-
isolation bacteria were grown for 3 d on BCYE plates, and liquid cultures were 
inoculated in AYE broth at an OD600 of 0.1 and grown for 21 h at 37°C (post-
exponential growth phase). For in vivo infections, bacteria were grown overnight to 
an OD600 of 1 in AYE broth. For all infections bacterial numbers were calculated 
by assuming that an OD600 of 1 corresponds to 10
9 bacteria/ml. 
4.2 Mice 
All animal experiments were approved by institutional and governmental animal 
welfare committees. All mice used were on C57BL/6J background, 8 - 10 weeks 
old and female. Ifnar-/- 284, Ifngr-/- 285, Ifnar/Ifngr-/- 185 and WT control mice were 
provided by Dr. Uwe Klemm (Max Planck Institute for Infection Biology, Berlin, 
Germany). C57BL/6 CD45.1 mice and transgenic CD11c-DTR-GFP 286 mice were 
provided by Dr. Sammy Bedoui (The Department of Microbiology and 
Immunology, The University of Melbourne, Melbourne, Australia) and maintained 
at the University of Melbourne. 
4.3 Murine L. pneumophila infection model  
Mice were anesthetized by intraperitoneal (i.p.) injection of 80 mg/kg ketamine and 
25 mg/kg xylazine and transnasally inoculated with 1 × 106 or 1 × 107 
L. pneumophila JR32 wt or flaA in 40 μl PBS per mouse. Control groups were 
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sham-infected with 40 μl PBS. At indicated time points mice were anesthetized 
(160 mg/kg ketamine, 75 mg/kg xylazine), heparinized (60 μl 12,500 I.E.) and 
sacrificed by final blood withdrawal. Blood was collected and leukocytes quantified 
by flow cytometry. After exsanguination the lung was flushed with sterile 
0.9% NaCl via the pulmonary artery (except for lungs used for histological 
analysis) before lung was removed and used for further analyses. For survival 
analysis bodyweight and temperature were recorded every 12 h for 10 d. 
4.3.1 RNA extraction, microarray analysis and upstream regulator 
analysis 
Lungs were flushed via the pulmonary artery with sterile 0.9% NaCl and 
homogenized in Trizol (Life Technologies). Homogenized lungs were pooled 
(5 mice per group) and RNA extraction was carried out according to manufacturer’s 
instructions. RNA amounts were estimated with a NanoDrop 1000 UV-Vis 
spectrophotometer (Kisker) and RNA integrity was confirmed using an 
Agilent 2100 Bioanalyzer with a RNA Nano 6000 microfluidics kit (Agilent 
Technologies). Microarray analysis and data extraction was carried out by 
Dr. Hans-Joachim Mollenkopf (Max Planck Institute for Infection Biology, Berlin, 
Germany). Microarrays were performed as dual-color hybridizations. In order to 
compensate dye-specific effects and to ensure statistically relevant data, color-swap 
dye-reversal hybridizations were performed 287. RNA labeling was done with a two-
color Quick Amp Labeling Kit according the supplier’s recommendations (Agilent 
Technologies). In brief, mRNA was reverse transcribed and amplified using an 
oligo-dT-T7 promoter primer, and labeled with cyanine 3-CTP or cyanine 5-CTP. 
After precipitation, purification, and quantification, 1.25 μg of each labeled cRNA 
was fragmented and hybridized to whole mouse genome 4x44k multipack 
microarrays (Design ID 014868) according to the manufacturer’s protocol (Agilent 
Technologies). Scanning of microarrays was performed with 5 μm resolution using 
a G2565CA high-resolution laser microarray scanner (Agilent Technologies) with 
XDR extended range. Microarray image data were analyzed and extracted with the 
Image Analysis/Feature Extraction software G2567AA v. A.10.10.1.1 (Agilent 
Technologies) using default settings and the protocol GE2_1010_Sep10. The 
extracted MAGE-ML files were subsequently analyzed with the Rosetta Resolver, 
Build 7.2.2 SP1.31 (Rosetta Biosoftware). Ratio profiles comprising single 
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hybridizations were combined in an error-weighted fashion to create ratio 
experiments. A 1.5-fold change expression cut-off for ratio experiments was 
applied together with anti-correlation of ratio profiles, rendering the microarray 
analysis highly significant (p < 0.01), robust, and reproducible. Genes identified to 
be significantly up-regulated upon L. pneumophila infection (> 2-fold increase, 
p < 0.05 in infected versus PBS-treated mice) were analyzed for their predicted 
upstream regulators using the Ingenuity Pathway Analysis (IPA) software 
(Ingenuity System). Only upstream regulators with an activation z-score > 2 
(predicted activators) were considered and further categorized in respective groups. 
4.3.2 Determination of bacterial counts  
Lungs were homogenized using a cell-strainer (100 µm, BD Bioscience). For 
determination of bacterial counts, the homogenates were lysed with 
0.2% Triton X-100 for 10 min and serial dilutions were plated on BCYE agar 
plates. 
4.3.3 Pulmonary leukocyte and blood leukocyte quantification  
Pulmonary leukocytes were differentiated manually by light microscopy of May-
Grünwald-Giemsa-stained cytospin preparations from lung homogenate prior to 
lysis. Leukocytes in the blood were analyzed by flow cytometry according to their 
side-scatter/forward-scatter properties and CD45 and Gr-1 expression. Briefly, red 
blood cells were removed using RBC Lysis Buffer (BD Biosciences) according to 
the manufacturer’s recommendations and cell suspension was labelled with 
anti-CD45 (BD Pharmingen) and anti-Gr-1 (BD Pharmingen). Cells were analyzed 
on a Becton Dickinson FACSCalibur flow cytometer using CELLQuest software 
(BD Biosciences). 
4.3.4 Histology 
Anesthetized mice were heparinized by intracardial injection through the intact 
diaphragm and sacrificed by exsanguination via direct incision of the caudal Vena 
cava. Then, lungs were removed after tracheal ligation to exclude alveolar collapse 
and fixed in 4% formalin (pH 7.0). Immersion formalin-fixed lungs were embedded 
in paraffin, cut and stained with hematoxylin and eosin. Paraffin embedding, 
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cutting, staining and image acquisition were carried out by Dr. Olivia Kershaw 
(Department of Veterinary Pathology, Free University Berlin, Berlin, Germany). 
4.3.5 Generation of bone marrow chimeric mice 
Chimeric mice were generated by Andrew S. Brown (The Department of 
Biochemistry and Molecular Biology, The University of Melbourne, Melbourne, 
Australia) as described recently 288. Briefly, CD45.1 mice were lethally irradiated 
twice with 550 cGy and reconstituted with a 1:1 mix of 1.5 × 106 bone marrow cells 
from C57BL/6 WT or Ifnar/Ifngr-/- and transgenic CD11c-DTR-GFP mice (all 
CD45.2). Chimeric mice were allowed to reconstitute for at least 10 weeks. Only 
those mice that contained < 10% host cells were included in experiments. Depletion 
of CD11c+ cells was achieved by injection of CD11c-DTR-GFP chimeric mice 
intraperitoneally three times with 100 ng diphtheria toxin (Sigma) on days -2, +1 
and +4 prior to and during infection. 
4.3.6 Evaluation of cell exchange rate and depletion efficiency in 
chimeric mice 
Lungs were finely minced using scissors and enzymatically digested in 3 ml of 
RPMI-1640 media supplemented with 3% fetal calf serum, 0.1% DNAse and 
0.1% collagenase type III. Tissue digestion was achieved by constant and gentle 
pipetting for 20 min at room temperature. Undigested tissue was filtered out and 
red blood cells were removed using RBC Lysis Buffer (BD Biosciences) according 
to the manufacturer’s recommendations. The lung cell suspension was labelled with 
anti-panCD45 (eBioscience), anti-CD45.1 (BD Pharmingen), anti-CD45.2 (BD 
Pharmingen), anti-Ly6G (BD Pharmingen), anti-CD11c (eBioscience) 
anti-MHC-II (eBioscience), anti-SiglecF, (BD Pharmingen) and anti-CD64 (BD 
Pharmingen). Cells were analyzed on a Becton Dickinson LSRFortessa flow 
cytometer using FACSDIVA software (BD Biosciences). 
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4.4 Cell culture 
4.4.1 Alveolar macrophage isolation 
For alveolar macrophages (AMs) isolation mice were anesthetized (160 mg/kg 
ketamine, 75 mg/kg xylazine), and sacrificed by final blood withdrawal. Afterwards 
the lungs were lavaged 10-times with 500 µl ice cold PBS + 0.5 mM EDTA. BAL 
fluid was centrifuged at 200 g for 10 min, cells resuspended in RPMI 1640 + 
10% FCS + 4.5 mM L-glutamine + 100 μg/ml Pen/Strep at a density of 
4 × 105 cells/ml and seeded in desired well-format one day before the experiment. 
For purity check cells were stained with anti-CD45 (BD Pharmingen), anti-SiglecF 
(eBioscience) and anti-CD11c (eBioscience) and analyzed on a MACSQuant 
(Miltenyi Biotec) flow cytometer. 
4.4.2 Generation of bone marrow-derived macrophages 
Isolation and culturing of bone marrow-derived macrophages (BMMs) was 
performed as described previously 289. Bone marrow was isolated from the femurs 
and tibiae. The bones were washed in 70% ethanol and then rinsed with RPMI 1640. 
Afterwards, the bones were disrupted with a pestle in a sterilized mortar in 20 ml 
RPMI 1640. Cell suspension was passed through a 70 μm cell strainer and 
centrifuged at 200 g for 10 min. Cells were resuspended in FCS + 10% DMSO and 
stored at -80°C in aliquots of 107 cells/ml in liquid nitrogen. For generation of bone 
marrow-derived macrophages (BMMs), bone marrow aliquots were thawed and 
transferred into BMM growth medium (RPMI 1640 + 20% FCS + 30% L929 
fibroblast supernatant + 4.5 mM L-glutamine + 100 μg/ml Pen/Strep). Cells were 
washed with BMM growth medium, resuspended in 20 ml BMM growth medium 
and divided into two petri dishes. 10 ml growth medium were added to each dish 
after 4 d of cultivation. After 10 d, confluent cells were incubated in 7 ml ice cold 
PBS + 2 mM EDTA and detached by scraping. Cells were resuspended in BMM 
replating medium (RPMI 1640 + 10% FCS + 15% L929 fibroblast supernatant + 
4.5 mM L-glutamine) at a density of 4 × 105 cells/ml and seeded in desired well-
format one day before the experiment. For medium preparation, L929 fibroblast 
were cultured in RPMI 1640 + 10% FCS + 4.5 mM L-glutamine for 10 d and 
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supernatant was harvested, sterile-filtered (0.2 μm) and stored at -80°C. All cells 
were cultured at 37°C and 5% CO2.  
4.4.3 Cell transfection 
BMMs and AMs were transfected with control non-silencing or a mix of two gene-
specific siRNAs (Table 4-1) (Life Technologies) using HiPerfect, according to the 
manufacturer’s protocol, using 19 ng siRNA in total and 1.5 μl HiPerfect reagent 
per 1 × 105 cells. Cells were infected 24 h post transfection and knock-down 
efficiency was assessed by qRT-PCR 24 h p.i. (48 h post transfection).  
 
Table 4-1 Oligonucleotides used for RNAi. 
 
target gene siRNA ID  target gene siRNA ID 
Cxcl10 s201504  Ifnar1 s68086 
Cxcl10 s68048  Irg1(#1) s68386 
Gbp2 s66501  Irg1(#2) s68387 
Gbp2 s66503  Nmes1 s119452 
Gbp3 s79881  Nmes1 s119453 
Gbp3 s79882  Rsad2 s81519 
Gbp7 s106347  Rsad2 s81520 
Gbp7 s106348  Slfn5 s116120 
Ifit1 s68058  Slfn5 s116121 
Ifit1 s68059  Themis2 s106616 
Ifnar1 s68085  Themis2 s106617 
For overexpression Ifnar-/- BMMs were transfected with 0.8 µg plasmid DNA 
encoding for EGFP (pEGFP-N1, Clontech) or full-length murine IRG1 
(NM_008392) with a carboxy-terminal TurboGFP (pCMV6-AC-GFP, OriGene) or 
Myc-DDK (pCMV6-Entry, OriGene) tag using 2.4 µl ViaFect per 2 × 105 cells 
according to manufacturer’s recommendations. Cells were incubated for 48 h post 
transfection to ensure efficient expression of the respective construct. 
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4.4.4 Cell stimulation and infection 
BMMs and AMs were infected with L. pneumophila wt or flaA at the indicated 
multiplicity of infection (m.o.i.), centrifuged at 200 g for 5 min and incubated for 
the indicated time intervals. Where indicated, cells were incubated either with 
IFN, IFN or both 16-18 h prior to and during infection.  
4.4.5 In vitro intracellular replication assays 
Intracellular L. pneumophila replication assays in BMMs and AMs were performed 
by infecting 1 × 105 or 4 × 104 cells per 48-well or 96-well, respectively at an m.o.i. 
of 0.1 or 1. The plates were centrifuged at 200 g for 5 min and subsequently 
incubated at 37°C for 30 min. Cells were washed twice with PBS and then incubated 
with RPMI containing 50 μg/ml gentamicin for 1 h at 37°C in order to kill 
extracellular bacteria. Subsequently, cells were washed twice with PBS and 
incubated in BMM replating medium for different time intervals. At indicated time 
points, cells were lysed by addition of 0.1% saponin and vigorous pipetting. 10 μl 
of serial dilutions from the lysed cells were plated on BCYE agar plates and 
incubated for 3 d at 37°C to determine bacterial CFUs.  
4.4.6 Cell death measurement 
For determination of cell death by flow cytometry BMMs were seeded in 
suspension cell 24-well plates and infected with eGFP expressing L. pneumophila, 
as described above. At indicated time points supernatants were collected and cells 
were detached by addition of ice cold PBS containing 2 mM EDTA and gentle 
pipetting. Respective supernatants and cells were subsequently pooled, centrifuged 
at 350 g 5 min and stained for cell death using 7-AAD or LIVE/DEAD fixable red 
dead cell stain according to manufacturer’s recommendations. Proportions of dead 
(7AAD+ or LIVE/DEAD+) cells were determined in infected (GFP+) and uninfected 
(GFP-) cell populations using a FACSScan or MACSQuant flow cytometer. Data 
analysis was done using FlowJo software (Tree Star). 
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4.5 LCV isolation and subsequent analyses 
4.5.1 LCV isolation 
LCVs from BMMs were isolated as described previously for RAW264.7 cells and 
amoeba 216. A total of 6 × 107 BMMs per condition were seeded in 4 T75 cell culture 
flasks one day before the experiment. Where indicated cells were stimulated with 
50 U/ml of recombinant murine IFN or IFN 16-18 h prior to the infection. Cells 
were infected with DsRed-expressing L. pneumophila JR32 flaA at an m.o.i. of 
50, centrifuged at 300 g for 10 min and incubated for 2 h at 37°C. Cells were then 
washed with PBS, scraped in 3 ml homogenization buffer (20 mM Hepes, 250 mM 
sucrose, 0.5 mM EGTA, pH 7.2) per flask and cells from corresponding flasks were 
pooled. Using a ball homogenizer with an exclusion size of 8 µm cells were 
homogenized by passing them 9-times through the cell homogenizer. Homogenates 
were incubated with 2% FCS for 30 min at 4°C followed by incubation with a rabbit 
anti-SidC antibody (1:3000) for 1 h at 4°C. After centrifugation at 1600 g at 4°C 
for 15 min, cells were resuspended in homogenization buffer and incubated with a 
secondary MACS anti-rabbit antibody (1:25) coupled to magnetic beads (Miltenyi 
Biotec) for 30 min at 4°C. Subsequently LCVs were separated using MiniMACS 
cell separation columns (Miltenyi Biotec), washed 3-times with homogenization 
buffer on the columns and eluted in homogenization buffer. The eluate was then 
applied on a continuous Histodenz density gradient (11 ml, from 10% to 35%) and 
centrifuged at 3500 g at 4°C for 1 h. 1.5 ml fractions were taken from the bottom 
of the tube. Fractions were centrifuged at 13000 g at 4°C for 15 min and pellets 
washed once with PBS, frozen in liquid nitrogen and stored at -80°C until further 
analysis. 
During the isolation process, samples were collected from the homogenized cells, 
the flow through of the MACS cell separation columns, the eluate and all fractions 
of the Histodenz gradient. All samples were centrifuged on coverslips, fixed with 
4% PFA for 20 min at RT and stained for SidC using a rabbit anti-SidC antibody 
and a secondary Cy5-labled anti-rabbit antibody to check the isolation process and 
identify the LCV-containing fractions by confocal microscopy. 
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4.5.2 Proteomic analysis 
Mass spectrometry analyses and protein identification and quantification were 
performed by Dr. Brian D. Dill and Dr. Matthias Trost (MRC Protein 
Phosphorylation Unit, University of Dundee, Dundee, UK). 
Isolated LCV from 4 IFN, 5 IFN, and 6 untreated biological replicates were 
solubilized in 1% RapiGest (Waters) in 50 mM Tris pH 8.0, reduced with 10 mM 
tris(2-carboxyethyl)phosphine (TCEP) (Pierce), and heated at 70°C for 10 min. 
After cooling, proteins were alkylated in 10 mM iodoacetamide (Sigma-Aldrich), 
and alkylation was quenched in 20 mM DTT. Protein concentrations were measured 
by the EZQ assay (Life Technologies), and 8 µg of protein was digested by trypsin 
overnight at 30°C, after diluting the Rapigest concentration to 0.1%. Rapigest was 
removed from the sample by acidification to 2% trifluoroacetic acid (TFA) and 
incubation at 37°C for 1 h, followed by centrifugation at 14000 g for 30 min. 
Peptides were then desalted with Microspin C18 solid phase extraction columns 
(The Nest Group). After drying down, peptides were redissolved in 1% TFA. 
For each sample, 2 µg of peptides were analyzed on an Orbitrap Velos Pro mass 
spectrometer coupled to an Ultimate 3000 UHPLC system with a 50 cm EasySpray 
analytical column (75 μm ID, 3 μm C18) in conjunction with a Pepmap trapping 
column (100 μm x 2 cm, 5 μm C18) (Thermo-Fisher Scientific). Acquisition 
settings were: lockmass of 445.120024, MS1 with 60000 resolution, top 20 CID 
MS/MS using Rapid Scan, monoisotopic precursor selection, unassigned charge 
states and z=1 rejected, dynamic exclusion of 60s with repeat count 1. 6 h linear 
gradients were performed from 3% solvent B to 35% solvent B (solvent A: 0.1% 
formic acid, solvent B: 80% acetonitrile 0.08% formic acid) with a 30 min washing 
and re-equilibration step 290. 
Protein identification and quantification were performed using MaxQuant Version 
1.4.1.2 291 with the following parameters: stable modification carbamidomethyl (C); 
variable modifications of methionine oxidation, and protein N-terminal acetylation, 
and 2 missed cleavages. Searches were conducted using a Uniprot-Trembl Mus 
musculus database downloaded May 1, 2013, L. pneumophila strain Philadelphia 1 
downloaded December 4, 2013, and common contaminants. Identifications were 
filtered at a 1% false-discovery rate (FDR) at the protein level, accepting a 
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minimum peptide length of 7. Quantification used only razor and unique peptides, 
and required a minimum ratio count of 2. “Re-quantify” and “match between runs” 
were enabled. Protein quantification was conducted using label-free quantitation 
(LFQ) intensities 292. 
4.5.3 Gene ontology analysis 
The 2307 host proteins identified in all six LCV samples from untreated 
macrophages were analyzed for overrepresented cellular components using 
g:Profiler (http://biit.cs.ut.ee/gprofiler/) 293,294 with default settings including g:SCS 
algorithm for multiple testing correction. All overrepresented child terms of the GO 
term intracellular membrane-bounded organelle (GO:0043231, p = 3.55 × 10-300) 
were extracted. To identify and visualize biological processes that are 
overrepresented at LCVs of untreated cells, the same list of proteins was analyzed 
with BiNGO 295 for Cytoscape 296 using default settings including hypergeometric 
testing and Benjamini & Hochberg FDR correction. Significance level cut-off was 
set to < 10-10 (terms with p-values > 10-10 are depicted if p-value of final child term 
was < 10-10). 
4.5.4 Integrated STRING network analysis 
Proteins identified in IFN-treated (in 4 of 4 IFN or 5 of 5 IFNtreated samples) 
but not in untreated samples (≤ 1 of 6 samples; hereafter called “qualitative 
changers”) and proteins with significant higher abundance in IFN-treated versus 
untreated samples (log2 LFQ intensity ratio ≥ 1, p < 0.05; hereafter called 
“quantitative changers”) were combined and analyzed for protein-protein 
interaction networks using STRING database (http://string-db.org/). The identified 
network was extracted and loaded into Cytoscape 296 for visualization; only 
interactions with a minimum STRING combined score of 0.400, which represents 
the default medium confidence level in STRING, were kept. For identification of 
subnetworks of overrepresented biological functions, the combined protein list was 
analyzed by g:Profiler (http://biit.cs.ut.ee/gprofiler/) 293,294. Protein lists of 
overrepresented GO terms were extracted and subnetworks were built using 
STRING and Cytoscape. To identify proteins within the networks that were also 
transcriptionally induced by IFNs upon in vivo L. pneumophila infection, the 
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combined list of qualitative and quantitative changing proteins was compared to 
genes with a > 2-fold change (p < 0.05) in L. pneumophila infected Ifnar/Ifngr-/- 
versus WT mice. To cross-reference gene names from transcriptome analysis and 
Uniprot identifier from proteome analysis, both lists were uploaded to STRING and 
respective output lists were compared against each other. For identification of 
known ISGs the protein list was also compared against the INTERFEROME 
database of ISGs 218. 
4.6 Molecular biology methods 
4.6.1 Total RNA isolation and cDNA synthesis  
Total RNA was isolated from BMMs or lung homogenates using the PerfectPure 
RNA purification system or Trizol, respectively, according to the manufacturer’s 
protocol. Subsequently, RNA was reverse-transcribed into cDNA using high 
capacity reverse transcription (HCRT) kit according to the manufacturer’s 
suggestions. 
4.6.2 Quantitative real time-PCR 
 cDNA obtained from HCRT was subjected to quantitative real time-PCR (qRT-
PCR). qRT-PCR was performed using TaqMan assays (Table 4-2) or self-designed 
primer sets (Table 4-3), respectively, on an ABI 7300 instrument.  
Table 4-2 TaqMan assays used for quantitative real-time PCR in this study. 
target gene Taqman assay ID 
Gbp7 Mm00523797_m1 
Ifit1 Mm00515153_m1 
Ifnar1 Mm00439544_m1 
Slfn5 Mm00806095_m1 
 
Primer design was done using PrimerExpress 3.0 software (Applied Biosystems) 
and self-designed oligonucleotides were dissolved in ddH2O yielding a 
concentration of 18 nmol/ml for forward and reverse primer and 5 nmol/ml for the 
5’-FAM-3’-TAMRA-labeled probe. For each sample a 20 µl qRT-PCR-reaction 
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(10 μl TaqMan Gene Expression Master, 4 µl ddH2O 1 µl of respective TaqMan 
assay or self-designed primer/probe mix and 5 μl cDNA) was transferred into a 96-
well plate and qRT-PCR performed using the following conditions: 2 min at 50°C, 
10 min at 95°C followed by 40 amplification cycles (15 sec at 95°C, 1 min at 60°C). 
Automatic baseline and automatic Ct were applied and raw data extracted. Data 
analysis was done using the 2-Ct method 297. The input was normalized to the 
average expression of Gapdh and relative expression (relative quantity, RQ) of the 
respective gene in untreated cells or PBS-treated mice were set as 1. 
Table 4-3 Primer sets used for quantitative real-time PCR in this study. 
target 
gene 
forward primer 
sequence (5' - 3') 
revers primer 
sequence (5' - 3') 
probe sequence  
 (5'-FAM, 3'-
TAMRA) 
Cxcl10 
CATCCCTGCGAGCCTA
TCC 
GGATTCAGACATCT
CTGCTCATCA 
CCCACGTGTTGAGAT
CATTGCCACG 
Gapdh 
TGTGTCCGTCGTGGAT
CTGA 
CCTGCTTCACCACC
TTCTTGA 
CCGCCTGGAGAAAC
CTGCCAAGTATG 
Gbp2 
GTTGAGAAGGGTGAC
AACCAGAA 
TGGTTCCTATGCTG
TTGTAGATGAA 
CTGGATCTTTGCTTT
GGCAGTCCTCCTC 
Gbp3 
AAGTCCTACCTCATGA
ATCGTCTTG 
ACCCTTGGTTTCGG
ATTGC 
AACCATGGCTTCTCC
TTGGGCTCC 
Irg1 
AGGCACAGAAGTGTT
CCATAAAGTC 
AGTGAACAGCAAC
ACCATTAACAAA 
AGACTTCAGGCTCCC
ACCGACATATGCT 
Nmes1 
TCAACCCCAAAAGCT
TATAACCA 
CCCTCCGGACTTTT
TGCA 
CAACCAGCAATGGA
AGCCCGTTG 
Rsad2 
TGGTGCCTGAATCTAA
CCAGAA 
TCCACGCCAACATC
CAGAAT 
CGCTTTCTGAACTGT
ACCGGTGGCC 
Themis2 
TGATCCTAAAACCCC
AGTATATGCT 
GACGGGATCTTGAC
GATGCT 
CAAGCCATCATGCA
CATGCGCA 
4.6.3 Immunoblotting 
For western blot analysis, cells were washed with washing buffer and lysed by 
scraping on ice with 100 μl lysis buffer per 1 × 106 cells. Cytoplasmic fraction was 
separated from nuclei by centrifugation at 16,000 g for 10 min at 4°C. Protein 
concentration was determined using Bradford reagent according to the 
manufacturer’s protocol. 5 μl of protein lysate were added to 1 ml of 20% Bradford 
reagent in H2O, mixed and OD595 measured. Protein concentrations were calculated 
assuming that an OD595 of 1 corresponds to 15.765 μg protein per μl. Proteins were 
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denatured at 95°C for 5 min together with loading buffer in a ratio of 1:1 and 40 µg 
total protein separated on a 10% SDS-gel at 80-120 V for 1h. SDS-polyacrylamide 
gels were blotted onto Hybond nitrocellulose membranes at 100 V for 1 h using a 
wet blot system (BioRad). Membranes were blocked in Odyssey Blocking Buffer 
for at least 1 h at RT or overnight at 4°C and probed with antibodies against IRG1 
(HPA040143, Sigma) and actin (sc-1616, Santa Cruz) followed by respective 
fluorophore-linked secondary antibodies (Rockland). Blots were analyzed using an 
Odyssey infrared imaging system (Li-Cor). All buffers and gels used for western 
blot analyses are listed in Table 4-4. 
Table 4-4 Buffers and gels used for western blot analysis. 
Buffer/Gel Composition 
Phosphoprotein 
washing buffer 
5 ml Sodium orthovanadate 98% (200 mM) 
50 ml Sodium pyrophosphate (150 mM) 
50 ml Sodium fluoride 99% (1 M) 
ad 395 ml ddH2O 
Lysis buffer 810 µl Phosphoprotein washing buffer 
100 μl Tris-HCl, pH 7,4 (500 mM) 
50 µl NP40 (20%) 
40 µl cOmplete protease inhibitor cocktail (25-fold) 
Loading buffer 1 ml Tris-HCl, pH 6.8 (500 mM) 
0.8 ml Glycerol 
1.6 ml SDS (10% w/v) 
0.4 ml Bromophenol blue (1% w/v) 
0.4 ml -Mercaptoethanol (1% v/v) 
3.8 ml ddH2O 
Electrophoresis buffer 3 g Tris-Base 
14.4 g Glycin 
1 g SDS 
ad 1000 ml ddH2O 
Blot buffer 3 g Tris-Base 
14.4 g Glycin 
200 ml Methanol 
ad 1000 ml ddH2O 
SDS Collection gel 2,5 ml Tris-HCl, pH 6,8 (500 mM) 
100 μl SDS (10% w/v) 
1,33 ml Bis-acrylamide (40%) 
10 μl TEMED 
50 μl Ammonium persulfate (10%) 
6 ml ddH2O 
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SDS Separation gel 
(10 %) 
2,5 ml Tris-HCl, pH 8,8 (1,5 M) 
100 μl SDS (10% w/v) 
2,5 ml Bis-acrylamide (40%) 
10 μl TEMED 
50 μl Ammonium persulfate (10%) 
4,85 ml ddH2O 
4.6.4 Immunofluorescence microscopy 
BMMs were seeded on glass coverslips in 24-well plates and fixed at indicated time 
points post infection with 3% PFA for 20 min at RT. Alternatively, cells were 
seeded in 6-well plates, cell homogenates generated as described in chapter 4.5.1, 
homogenates centrifuged onto glass coverslips and fixed with 3% PFA for 20 min 
at RT. For intracellular staining, cells were permeabilized with 0.1% Triton X-100 
in PBS for 15 min at RT, blocked with 5% FCS in PBS for 20 min at RT, stained 
with an affinity purified rabbit anti-SidC antibody for 2-3 h at RT or overnight at 
4°C, followed by Alexa Fluor 488- or Alexa Fluor 633-conjugated secondary 
antibody (Molecular Probes) for 1 h at RT, and mounted on slides using PermaFluor 
containing DAPI. Samples were examined with a LSM 780 microscope 
([objectives: Plan Apochromat 63×/1.40 oil DIC M27]. Z-stack was taken with a 
63x objective over 5.44 µm in 680 nm plane distance. Images were processed using 
ZEN 2010 (Zeiss) and ImageJ software (http://imagej.nih.gov/ij/). 
4.6.5 GC/MS analysis 
106 BMMs per 6-well were left untreated, were incubated either with IFN or IFN 
for 16-18 h or were infected with L. pneumophila at an m.o.i. of 10 for 24 h. Where 
indicated cells were transfected with control non-silencing or a mix of two gene-
specific siRNAs as described above 24 h prior to infection. After washing with PBS, 
metabolism was stopped adding 200 µl cooled 50% MeOH (-20°C) and cells were 
collected by scraping in the MeOH solution. Cells from 6 wells were pooled, 240 µl 
chloroform were added, samples centrifuged for 10 min at 10000 g and supernatant 
containing polar metabolites was dried under vacuum overnight. For in vivo 
experiments mice were infected with L. pneumophila wt or left untreated. 2 d p.i. 
lungs were flushed with sterile PBS, shock frozen in liquid nitrogen and stored at -
80°C. Lung tissue was homogenized using a Precellys24 bead homogenizer in 
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chloroform (6 mL/g), methanol (6 mL/g), and distilled water (4 mL/g). Samples 
were centrifuged for 10 min at 10000 g and supernatant containing polar 
metabolites was dried under vacuum overnight. GC/MS analysis was performed by 
Dr. Stefan Kempa (Integrative Metabolomics and Proteomics, Berlin Institute of 
Medical Systems Biology/Max-Delbrueck Center for Molecular Medicine, Berlin, 
Germany) and samples were processed using protocols and machine settings 
described elsewhere 298. Data were analyzed using ChromaTOF (Leco) and the 
custom software MetMax 299. Data were normalized on mean of total area of all 
analyzed metabolites (in vitro samples) or on internal standard (cinnamic acid; 
in vivo samples) and average relative amount of itaconic acid in untreated cells or 
control mice was set as 1. 
4.6.6 Itaconic acid growth inhibition and killing assay 
For growth inhibition bacteria were grown in AYE broth containing indicated 
amounts of itaconic acid and OD was determined over time.  
4.7 Statistical analyses 
Experiments were performed in a non-randomized and unblinded fashion. Data 
were statistically analyzed using GraphPad Prism software. Two groups were 
compared with two-tailed Mann-Whitney U test or, for multiple-group comparisons 
with Kruskal-Wallis analysis of variance followed by Dunn’s multiple comparison 
test or two-way ANOVA followed by Bonferroni posttest. Differences with 
p < 0.05 were considered statistically significant. 
4.8 Reagents, kits, consumables and instruments 
Table 4-5 Reagents 
Reagent Company 
7-AAD eBioscience 
ACES Sigma 
Ammonium persulfate  Serva 
Ampicillin  Ratiopharm 
Ampuwa® (RNase-free H2O)  Fresenius Kabi 
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Bacto yeast extract  BD Biosciences 
Bis-acrylamide  Serva 
Bradford solution  BioRad 
Bromphenol blue  Biotech Pharmacia 
Chloramphenicol  Sigma 
Chloroform Merck 
Collagenase type III Worthington-Biochemical 
cOmplete protease inhibitor cocktail tablets  Roche 
Cyteine  Sigma 
DAPI Invitrogen 
DMSO  Sigma 
DNase  Sigma 
EDTA  Roth 
EGTA Sigma 
Ethanol  Merck 
FCS  PAA 
Ferric nitrate  Sigma 
Gentamicin  Gibco 
Glutamine  PAA 
Glycerol  Roth 
Glycine  Sigma 
Heparine  Ratiopharm 
HEPES  Biochrom 
HiPerfect Qiagen 
Histodenz Sigma 
Hybond nitrocellulose membrane  Santa Cruz 
Isopropanol  Sigma 
Itaconic acid Sigma 
Kanamycin  Sigma 
Ketamine (Ketavet)  Sigma 
L-glutamine  PAA 
LIVE/DEAD fixable red dead cell stain Life Technologies 
Methanol  Merck 
mIFN PBL interferon source 
mIFN PBL interferon source 
NaCl (0.9%)  B. Braun 
NP40 Sigma 
Odyssey blocking buffer  Li-COR 
Paraformaldehyde  Sigma 
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PBS  Gibco 
Penicillin/streptomycin  PAA 
PermaFluor  Beckmann Coulter 
poly-L-lysine  Sigma 
RBC lysis buffer BD Bioscience 
RBC lysis buffer 10X  BioLegend 
RPMI 1640  Gibco 
Saponin  Sigma-Aldrich 
SDS  Serva 
Sodium fluoride  Sigma 
Sodium orthovanadate  Sigma 
Sodium periodate  Sigma 
Sodium pyrophosphate  Sigma 
Sucrose  Sigma 
TaqMan® Gene Expression Master Mix Applied Biosystems 
TEMED  R&D Systems 
Tris-HCl  Sigma 
Triton X-100  Sigma 
TRIzol®  Invitrogen 
Tween-20  Sigma-Aldrich 
ViaFect Promega 
Xylazine (Rompun)  Bayer 
Yeast extract  BD Biosciences 
-mercaptoethanol  Sigma 
Table 4-6 Kits 
Kit Company 
PerfectPure RNA cultured cell kit  5 PRIME 
PerfectTaq™ plus DNA polymerase  5 PRIME 
HCRT  Applied Biosystems 
Plasmid purification  Qiagen 
TaqMan gene expression assays  Applied Biosystems 
Table 4-7 Instruments 
Instrument Company 
7300 Real-Time PCR System  Applied Biosystems 
Ball homogenizer  Isobiotec 
BD FACSCalibur™  BD Biosciences 
BD FACSCanto™  BD Biosciences 
4.8 Reagents, kits, consumables and instruments 
 
87 
BD FACSScan™  BD Biosciences 
BD LSRFortessa™  BD Biosciences 
BioRad gelelectrophoresis  BioRad 
Cytospin 3  Shandon 
Heracell™ 240i CO2 incubator  Thermo Scientific 
Herasafe™ KS  Thermo Scientific 
LSM 780 microscope  Zeiss 
LSM 5 PASCAL microscope  Zeiss 
MACS® manual separators  Miltenyi Biotec 
MACSQuant Miltenyi Biotec 
Mastercycler  Gradient Eppendorf 
Microcentrifuge 5417R  Eppendorf 
NanoDrop 2000 T hermo Scientific 
Odyssey infrared imaging system  LI-COR Inc. 
Photometer  Eppendorf 
Rotanta 460 R  Hettich 
Thermomixer  Eppendorf 
Vortex mixer, VV 3  VWR 
Western blot system  Transblot 
Table 4-8 Consumables 
Consumable Company 
0.2 μm filters  BD Biosciences 
Cell culture flasks  BD Biosciences 
Cell culture tubes  Falcon 
Cell strainers (100 μm, 70 μm, 40 μm)  BD Biosciences 
Cuvettes Fisher Scientific 
Petri dish  BD Biosciences 
Serological pipets  Thermo Scientific 
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ABBREVATIONS 
(ds)RNA 
(double stranded) 
ribonucleic acid 
AIM2 absent in melanoma 2 
AM alveolar macrophage 
AMP 
adenosine mono-
phosphate 
APC antigen presenting cell 
ASC 
apoptosis-associated 
speck-like protein 
containing a carboxy-
terminal CARD 
BAL bronchoalveolar lavage  
BCG Bacille Calmette-Guérin 
BCR B cell receptor 
BIR 
baculovirus inhibitor of 
apoptosis repeat 
BMM 
bone marrow-derived 
macrophage 
CARD 
caspase activation and 
recruitment 
CASP1 caspase-1 
CFU colony forming unit 
cGAMP cyclic-GMP-AMP 
cGAS cGAMP synthase 
DAPI 
4',6-diamidino-2-
phenylindole 
DC dendritic cell 
DIC 
differential interference 
contrast 
DNA deoxyribonucleic acid 
DTR diphtheria toxin receptor 
DTX diphtheria toxin 
DUOX dual oxidase 
ER endoplasmic reticulum 
FADD 
Fas-associated death 
domain 
FcR 
fragment crystallizable 
(Fc) gamma receptor 
GAF gamma-activated factor 
GAS IFN activated site 
GBP guanylate binding protein 
GFP green fluorescent protein 
GMP 
guanosine mono-
phosphate 
GO gene ontology 
GTP guanosine tri-phosphate 
GVIN 
very large inducible 
GTPases 
HCV Hepatitis C virus 
ICL isocitrate lyase 
IFIT 
IFN-induced protein with 
tetratricopeptide repeats 
IFITM 
IFN- inducible 
transmembrane 
IFN interferon 
IFNAR interferon / receptor 
IFNGR interferon  receptor 
IL- interleukin- 
iNOS 
inducible nitrogen oxide 
synthase 
IRF 
interferon regulatory 
factor 
IRG immunity-related GTPase 
IRG1 immunoresponsive gene 1 
ISG 
interferone stimulated 
gene 
ISGF3 
IFNstimulated gene 
factor 3 
ISRE 
IFN-stimulated response 
elements 
JAK Janus kinase 
LAMP-1 
lysosome-associated 
membrane glycoprotein 1 
LCV 
Legionella-containing 
vacuole 
LFQ label free quantity 
Abbrevations 
 
91 
LGP2 
laboratory of genetics and 
physiology 2 
LPS lipopolysaccharide 
LRR leucine rich repeat 
m.o.i. multiplicity of infection 
MAVS 
mitochondrial antiviral 
signaling 
MCL methylisocitrat lyase 
MDA5 
melanoma differentiation 
antigen 5 
MDP muramyl dipeptide 
MHC 
major histocompatibility 
complex 
mROS mitochondrial ROS 
MX 
myxoma resistance 
protein 
MyD88 
myloid differentiation 
primary response gene 88 
NADPH 
nicotinamide adenine 
dinucleotide phosphate 
NAIP 
NLR family, apoptosis 
inhibitory protein 
NF-kB 
nuclear factor 'kappa-
light-chain-enhancer' of 
activated B-cells 
NK cell natural killer cell 
NLR NOD-like receptor 
NO nitrogen oxide 
NOD 
Nucleotide-binding, 
oligomerization domain 
NOX NADPH oxidase 
OAS oligoadenylate synthase 
p.i. post infection 
PAMP 
pathogen associated 
molecular pattern 
PBS phosphate buffered saline 
PCC 
propionyl-CoA 
carboxylase 
PRR 
pattern recognition 
receptor 
PYD pyrin domain 
qRT-
PCR 
quantitative real-time 
polymerase chain reaction 
Rab Ras-related in brain 
RIG-I 
retinoic acid-inducible 
gene I 
RIP1/3 
receptor-interacting 
protein 1/3 
RLR RIG-I-like receptor 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RQ relative quantity 
RT room temperature 
s.e.m. standard error of the mean 
SNARE 
soluble N-
ethylmaleimide-sensitive-
factor attachment receptor 
STAT 
signal transducer and 
activator of transcription 
STING 
stimulator of interferon 
genes 
T4SS type IV secretion system 
TCA tricarboxylic acid 
TCR T cell receptor 
TLR Toll-like receptor 
TNF tumor necrosis factor 
TRIF 
TIR-domain-containing 
adapter-inducing 
interferon-β 
TYK tyrosine kinase 
WT 
wild-type (concerning 
mice) 
wt 
wild-type (concerning 
bacteria) 
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